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Aortic Dissection {#Sec1}
=================

Differential Diagnosis {#Sec2}
----------------------

### Cardiac {#Sec3}

**[myocardial]{.smallcaps}**---myocardial infarction, angina**[valvular]{.smallcaps}**---aortic stenosis, aortic regurgitation**[pericardial]{.smallcaps}**---pericarditis**[vascular]{.smallcaps}**---aortic dissection

### Respiratory {#Sec4}

**[parenchymal]{.smallcaps}**---pneumonia, cancer**[pleural]{.smallcaps}**---pneumothorax, pneumomediastinum, pleural effusion, pleuritis**[vascular]{.smallcaps}**---pulmonary embolism, pulmonary hypertension

**GI**---esophagitis, esophageal cancer, GERD, peptic ulcer disease, Boerhaave's, cholecystitis, pancreatitis

**OTHERS**---musculoskeletal, shingles, anxiety

Pathophysiology {#Sec5}
---------------

**ANATOMY**---layers of aorta include intima, media, and adventitia. Majority of tears found in ascending aorta right lateral wall where the greatest shear force upon the artery wall is produced

**AORTIC TEAR AND EXTENSION**---aortic tear may produce a tearing, ripping sudden chest pain radiating to the back. Aortic regurgitation can produce diastolic murmur. Pericardial tamponade may occur, leading to hypotension or syncope. Initial aortic tear and subsequent extension of a false lumen along the aorta may also occlude blood flow into any of the following vascular structures:**[coronary]{.smallcaps}**---acute myocardial infarction (usually RCA)**[brachiocephalic, left subclavian, distal aorta]{.smallcaps}**---absent or asymmetric peripheral pulse, limb ischemia**[renal]{.smallcaps}**---anuria, renal failure**[carotid]{.smallcaps}**---syncope/hemiplegia/death**[anterior spinal]{.smallcaps}**---paraplegia/quadriplegia, anterior cord syndrome

### Classification Systems {#Sec6}

**S** **[tanford]{.smallcaps}**---**A** = any ascending aorta involvement, **B** = all others**D** **[e]{.smallcaps}** **B** **[akey]{.smallcaps}**---**I** = ascending and at least aortic arch, **II** = ascending only, **III** = originates in descending and extends proximally or distally

### Risk Factors {#Sec7}

**[common]{.smallcaps}**---hypertension, age, male**[vasculitis]{.smallcaps}**---Takayasu arteritis, giant cell arteritis, rheumatoid arthritis, syphilitic aortitis**[collagen disorders]{.smallcaps}**---Marfan syndrome, Ehlers--Danlos syndrome, cystic medial necrosis**[valvular]{.smallcaps}**---bicuspid aortic valve, aortic coarctation, Turner syndrome, aortic valve replacement**[others]{.smallcaps}**---cocaine, trauma

Clinical Features {#Sec8}
-----------------

**RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT HAVE AN ACUTE THORACIC AORTIC DISSECTION?LR+LR** **−History**Hypertension1.60.5Sudden chest pain1.60.3Tearing or ripping pain1.2--10.80.4--0.99**Physical**Pulse deficit5.70.7Focal neurological deficit6.6--330.71--0.87Diastolic murmur1.40.9**CXR/ECG**Enlarged aorta or wide mediastinum2.00.3LVH on ECG0.2--3.20.84--1.2**APPROACH**---"presence of tearing, ripping, or migrating pain may suggest dissection. Pulse deficit or focal neurological deficits greatly increase likelihood of dissection. Absence of pain of sudden onset decreases likelihood of dissection. Normal aorta and mediastinum on CXR help to exclude diagnosis"**JAMA 2002 287:17**

Investigations {#Sec9}
--------------

### Basic {#Sec10}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, troponin/CK ×3, glucose, AST, ALT, ALP, bilirubin, albumin, lipase, INR/PTT**[imaging]{.smallcaps}**---CXR, echocardiogram (TEE), CT chest or MRI chest**ECG**

### Special {#Sec11}

**[aortography]{.smallcaps}**

Diagnostic and Prognostic Issues {#Sec12}
--------------------------------

**CXR FINDINGS**---wide mediastinum (\>6 cm \[2.4 in.\]), indistinct aortic knuckle, pleural cap, difference in diameter between ascending and descending aorta, blurring of aortic margin secondary to local extravasation of blood, pleural effusion or massive hemothorax, displaced calcification (separation of the intimal aortic calcification from the edge of the aortic shadow \>1 cm \[0.4. in.\])

### Prognosis {#Sec13}

**[type a]{.smallcaps}**---with surgery, 1-month survival 75--80%, 10-year survival 55%**[type b]{.smallcaps}**---with aggressive hypertensive treatment, 1-month survival \>90%, 10-year survival 56%

Management {#Sec14}
----------

**ABC**---**O** ~**2**~ to keep sat \>95%, IV, **antihypertensive** (keep HR \<60 and SBP \<120 mmHg. *Labetalol* 2 mg/min IV loading drip, then 2--8 mg/min (target heart rate 55--60) or 20--80 mg IV q10min, maximum 300 mg, then 200--400 mg PO BID. If SBP still \>100 mmHg, *sodium nitroprusside* 0.25--0.5 μg/kg/min IV initially, then 0.25--10 μg/kg/min)

**TREAT UNDERLYING CAUSE**---**Type A** (emergent surgical repair, endovascular stenting, long-term blood pressure control). **Type B** (medical blood pressure control). Monitor over time with serial CT/MR chest**Related Topics**Acute Coronary Syndrome (p. 26)Stroke (p. 299)

Acute Coronary Syndrome {#Sec15}
=======================

**ACC/AHA 2004 STEMI Guidelines ACC/AHA 2007 STEMI Focused Update ACC/AHA 2007 UA/NSTEMI Guidelines**

Differential Diagnosis of Chest Pain {#Sec16}
------------------------------------

### Cardiac {#Sec17}

**[myocardial]{.smallcaps}**---myocardial infarction, angina (atherosclerosis, vasospasm)**[valvular]{.smallcaps}**---aortic stenosis**[pericardial]{.smallcaps}**---pericarditis**[vascular]{.smallcaps}**---aortic dissection

### Respiratory {#Sec18}

**[parenchymal]{.smallcaps}**---pneumonia, cancer**[pleural]{.smallcaps}**---pneumothorax, pneumomediastinum, pleural effusion, pleuritis**[vascular]{.smallcaps}**---pulmonary embolism

**GI**---esophagitis, esophageal cancer, GERD, peptic ulcer disease, Boerhaave's, cholecystitis, pancreatitis

**OTHERS**---musculoskeletal (costochondritis), shingles, anxiety

Pathophysiology {#Sec19}
---------------

**Pathologic changesClinical presentation**Pre-clinicalAtherosclerosisAsymptomaticAnginaLuminal narrowingCentral chest discomfort; worsened by exertion, emotion, and eating; relieved by rest and nitroglycerineUnstable anginaPlaque rupture or thrombusWorsening pattern or rest painNSTEMIPartial occlusionNon-ST elevation MISTEMIComplete occlusionST elevation MI

### Universal Definition of Myocardial Infarction (MI) {#Sec20}

**[type 1]{.smallcaps}**---spontaneous MI due to a primary coronary event (atherosclerotic plaque rupture or erosion with acute thromboembolism)**[type 2]{.smallcaps}**---MI due to supply--demand mismatch**[type 3]{.smallcaps}**---MI associated with sudden unexpected cardiac death**[type 4]{.smallcaps}**---MI associated with PCI (4A) or stent thrombosis (4B)**[type 5]{.smallcaps}**---MI associated with CABG

### Risk Factors {#Sec21}

**[major]{.smallcaps}**---diabetes, hypertension, dyslipidemia, smoking, family history of premature CAD, advanced age, male gender**[associated]{.smallcaps}**---obesity, metabolic syndrome, sedentary lifestyle, high-fat diet**[emerging]{.smallcaps}**---lipoprotein abnormalities, inflammation (↑ CRP), chronic infections, renal failure

**POST--** **MI** **COMPLICATIONS**---arrhythmia (VT/VF, bradycardia), sudden death, papillary muscle rupture/dysfunction, myocardial rupture (ventricular wall, interventricular septum), ventricular aneurysm, valvular disease (especially acute mitral regurgitation), heart failure/cardiogenic shock, pericarditis (Dressler's syndrome)

Clinical Features {#Sec22}
-----------------

**CHEST PAIN EQUIVALENTS**---dyspnea, syncope, fatigue, particularly in patients with diabetic neuropathy who may not experience chest pain

### New York Heart Association (NYHA) Classification {#Sec23}

**I** = no symptoms with ordinary physical activity**II** = mild symptoms with normal activity (walking \>2 blocks or 1 flight of stairs)**III** = symptoms with minimal exertion**IV** = symptoms at rest

### Canadian Cardiovascular Society (CCS) Classification {#Sec24}

**I** = angina with strenuous activity**II** = slight limitation, angina with meals/cold/stress**III** = marked limitation, angina with walking \<1--2 blocks or 1 flight of stairs**IV** = unstable angina**IV** **[a]{.smallcaps}** = unstable angina resolves with medical treatment**IV** **[b]{.smallcaps}** = unstable angina on oral treatment, symptoms improved but angina with minimal provocation**IV** **[c]{.smallcaps}** = unstable angina persists, not manageable on oral treatment or hemodynamically unstable

### Killip Class Classification {#Sec25}

**I** = no evidence of heart failure**II** = mild to moderate heart failure (S3, lung rales less than half way up, or jugular venous distension)**III** = overt pulmonary edema**IV** = cardiogenic shock

**RATIONAL CLINICAL EXAMINATION SERIES: IS THIS PATIENT HAVING A MYOCARDIAL INFARCTION?LR+History**Radiation to right shoulder2.9Radiation to left arm2.3Radiation to both arms7.1Nausea or vomiting1.9Diaphoresis2.0Pleuritic chest pain0.2Sharp or stabbing chest pain0.3Positional chest pain0.3Chest pain reproducible by palpation0.2--0.4**Physical**Hypotension3.1S33.2Pulmonary crackles2.1**ECG**New ST elevation ≥1 mm5.7--53.9New Q wave5.3--24.8Any ST elevation11.2New conduction defect6.3New ST depression3.0--5.2Any Q wave3.9Any ST depression3.2T wave peaking or inversion ≥1 mm3.1New T wave inversion2.4--2.8Any conduction defect2.7**APPROACH**---"radiation of chest pain, diaphoresis, hypotension, and S3 suggest acute MI. Chest pain that is pleuritic, sharp or stabbing, positional or reproduced by palpation decreases likelihood of acute MI. On ECG, any ST ↑, new Q waves, or new conduction Δ make acute MI very likely. Normal ECG is very powerful to rule out MI"**JAMA 1998 280:14**

Investigations {#Sec26}
--------------

### Basic {#Sec27}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, glucose, troponin/CK ×3 q8h, AST, ALT, ALP, bilirubin, INR/PTT, Mg, Ca, PO~4~, albumin, lipase, fasting lipid profile, HbA1C**[imaging]{.smallcaps}**---CXR, echocardiogram (first 72 h), MIBI/thallium (\>5 days later)**ECG**---q8h ×3 or with chest pain**[stress tests]{.smallcaps}**---ECG, echocardiogram, MIBI once stable (\>48 h post-MI)**CORONARY CATHETERIZATION**

Diagnostic and Prognostic Issues {#Sec28}
--------------------------------

### Risk Stratification for Stable Coronary Disease {#Sec29}

**ECG** **[exercise stress test]{.smallcaps}** **[absolute contraindications]{.smallcaps}**---recent myocardial infarction (\<4 days), unstable angina, severe symptomatic LV dysfunction, life-threatening arrhythmia, acute pericarditis, aortic dissection, PE, severe symptomatic aortic stenosis**[goal]{.smallcaps}**---keep on treadmill until subject reaches 85--90% of age-predicted heart rate (220--age)**[ischemia criteria]{.smallcaps}**---≥1 mm horizontal or down-sloping ST ↓ over multiple leads, or ST ↑ → myocardial ischemia (sens 68%, spc 77%) → proceed to angiogram**[inconclusive]{.smallcaps}**---premature termination due to chest pain/poor exercise tolerance → proceed to pharmacological stress test**[duke treadmill score]{.smallcaps}**---(exercise time in minutes) -- 5×(maximum ST ↓ in mm) -- 4×(treadmill angina index \[0=none, 1=non-limiting, 2=exercise limiting\]). **Low risk** ≥5 (4-year survival 98--99%), **moderate risk** --10 to +4, **high risk** ≤--11 (4-year survival 71--79%)**[dipyridamole/adenosine]{.smallcaps}** **MIBI**---dipyridamole (Persantine) causes vasodilation. In CAD, the coronary artery is already maximally dilated to compensate, so addition of dipyridamole will not change perfusion to diseased vessel(s) further. This results in a relative perfusion mismatch compared to areas with normal dilatory reaction. Contraindicated in asthma/COPD. Antidote is aminophylline or caffeine**[dobutamine echocardiography]{.smallcaps}**---assesses wall motion abnormalities. Compared to MIBI, echocardiogram is more specific and less sensitive. Contraindicated in severe hypertension and arrhythmias

**APPROACH TO DIAGNOSIS OF STABLE** **CAD**---start with history, physical, rest ECG, and CXR. If low probability, do not investigate further. If high probability, proceed with management. If intermediate probability → stress test → cardiac CT, MIBI or stress echo → angiography

### Differential Diagnosis of Troponin Elevation {#Sec30}

**[cardiac]{.smallcaps}**---myocardial infarction, myocarditis, congestive heart failure, pericarditis, vasospasm, tachycardia with hemodynamic compromise, cocaine ingestion**[pulmonary]{.smallcaps}**---pulmonary embolism**[hepatic]{.smallcaps}**---liver failure**[renal]{.smallcaps}**---chronic kidney disease**[neurologic]{.smallcaps}**---stroke, intracranial hemorrhage**[systemic]{.smallcaps}**---sepsis, prolonged strenuous exercise

### Serum Markers {#Sec31}

**[troponin i/t]{.smallcaps}**---rises within 4--6 h, peaks at 18--24 h, remains elevated 7--10 days (sens 40% at presentation, 40--70% after 6--9 h of symptoms)**CK/CKMB**---rises within 4--6 h, peaks at 18--24 h, remains elevated 3--4 days (sens 35--50% at presentation, 90% after 3 h in ER)**[myoglobin]{.smallcaps}**---rises within 1--2 h, peaks in few hours

Therefore, should do markers (e.g. troponin) at least twice separated by 6--8 h and serial ECG. Despite all appropriate investigations, MI missed rate is 2--5%

**ECG** **CHANGES IN ACUTE** **MI**---see APPROACH TO ECG p. 62

### Timi Score for Patients with Unstable Angina/Nstemi {#Sec32}

**[scoring]{.smallcaps}** (out of 7)---age ≥65, ≥3 CAD risk factors, known CAD (stenosis \>50%), ASA use within 7 days, ≥2 angina episodes within 24 h, ↑ cardiac marker, ST deviation ≥0.5 mm**[risk groups]{.smallcaps}**---**low** = 0--2, **intermediate** = 3--4, **high** = 5--7. Consider GPIIb/IIIa and early angiography with revascularization in intermediate or high-risk groups**[risk of death,]{.smallcaps}** **MI** **[or revascularization in 14 days]{.smallcaps}**---0/1=5%, 2=8%, 3=13%, 4=20%, 5=26%, 6/7=41%

### Timi Score for Patients with Stemi {#Sec33}

**[scoring]{.smallcaps}** (out of 14)---age (3 points= ≥75, 2 points=65--74), any of diabetes, hypertension, or angina (1 point), systolic BP ≤100 mmHg (3 points), HR \>100 (2 points), Killip II--IV (2 points), weight \<67 kg (1 point), anterior ST elevation or LBBB (1 point), time to reperfusion \>4 h (1 point)**[risk of death in 30 days]{.smallcaps}**---0=0.8%, 1=1.6%, 2=2.2%, 3=4.4%, 4=7.3%, 5=12.4%, 6=16.1%, 7=23.4%, 8=26.8%, \>8=35.9%

**IN-HOSPITAL OUTCOMESNSTEMISTEMI**Death4%6%Reinfarction0.9%1.1%Cardiogenic shock2.8%6.4%Stroke0.7%0.8%Major bleeding10%12%ACTION registry 2008/2009 data

Acute Management {#Sec34}
----------------

**ABC**---O~2~ to keep sat \>95%, IVs, inotropes, consider balloon pump if hemodynamic instability

**PAIN CONTROL**---**nitroglycerin** (*nitro drip* 25 mg in 250 mL D5W, start at 5 μg/min IV, then ↑ by 5--10 μg/min every 3--5 min to 20 μg/min, then ↑ by 10 μg/min every 3--5 min up to 200 μg/min, or until relief of pain, stop titration if SBP is \<100 mmHg. *Nitro patch* 0.4 mg/h daily. *Nitro spray* 0.4 mg SL q5min ×3. Beware if suspect right ventricular infarction or if patients on sildenafil). ***Morphine*** 2--4 mg IV every 5--15 min PRN

### Clot Control {#Sec35}

**[antiplatelet]{.smallcaps}**---***ASA*** 162--325 mg PO chew ×1 dose, then 75--162 mg PO daily (for medically treated unstable angina/NSTEMI), or 162--325 mg PO daily (post-PCI minimum ×1 month for bare-metal stent, ×3 months for sirolimus-eluting stent, or ×6 months for paclitaxel-eluting stent), then 75--162 mg PO daily indefinitely. If NSTEMI or STEMI, ***clopidogrel*** 300--600 mg ×1 dose then 75 mg PO daily. Combination ASA plus clopidogrel for minimum of 1 month (ideally 1 year)-post PCI with bare-metal stent, or minimum 12 months (possibly indefinitely) for drug-eluting stents. If post-PCI, pain unresponsive to nitroglycerin or intermediate/high-risk NSTEMI, consider **GPIIb/IIIa inhibitor** (*tirofiban* 0.4 μg/kg/min ×30 min IV, then continue 0.1 μg/kg/min ×18--24 h after angioplasty/atherectomy. *Eptifibatide* 180 μg/kg IV bolus, then 2 μg/kg/min ×72--96 h)**[anticoagulation]{.smallcaps}**---options include **LMWH** (*enoxaparin* 30 mg IV bolus, then 1 mg/kg SC BID for STEMI \[no IV bolus for NSTEMI caution if renal failure or age \>75) or **unfractionated heparin** (*unfractionated heparin* 70 U/kg \[up to 4000U\] IV bolus, then 18 U/kg/hr \[up to 1000U/h\] and adjust to 1.5--2.5× normal PTT for 72 h). **Factor Xa** **inhibitors** (*Fondaparinux* 2.5 mg SC daily until discharge or 8 days, caution if renal failure). **Direct thrombin inhibitors** (*Bivalirudin* 0.1 mg/kg IV bolus then 0.25 mg/kg/hr initially, followed by second 0.5 mg/kg bolus before PCI and 1.75 mg/kg/hr during PCI, then continue infusion for up to 4 h post-PCI, if needed)**[reperfusion therapy]{.smallcaps}**---see **PCI** for details. **Fibrinolytics** (*TPA* 15 mg IV over 2 min, then 0.75 mg/kg over 30 min \[maximum 50 mg\], then 0.5 mg/kg over 60 min \[overall maximum 100 mg\]. *Streptokinase* 1.5 million units IV over 30--60 min. *Tenectepalse* IV bolus over 10--15 s, weight-based: 30 mg for weight \<60 kg, 35 mg for 60--69 kg, 40 mg for 70--79 kg, 45 mg for 80--89 kg, 50 mg for ≥90 kg)

**[rate control]{.smallcaps}**---IV metoprolol is mostly contraindicated. Start with *metoprolol* 25 mg PO BID and titrate slowly. Alternatively, *atenolol* 25 mg PO daily and titrate to 100 mg PO daily. The goal heart rate is 50--55 with normal activity. If β-blocker contraindicated, consider non-dihydropyridine calcium channel blockers *diltiazem* 30--120 mg PO QID or *verapamil* 80--120 mg PO TID (contraindicated if LV dysfunction)

**[lipid control]{.smallcaps}**---*simvastatin* 40 mg PO daily or *atorvastatin* 80 mg PO daily

**[blood pressure support]{.smallcaps}**---for patients with cardiogenic shock, consider IV fluids, inotropes (dobutamine/dopamine), balloon pump, and early revascularization **OVERALL APPROACHStable anginaUnstable angina or NSTEMISTEMI**ASA✓✓✓Nitrates✓✓✓Morphine±✓✓β-blockers✓✓✓ACE inhibitors✓✓✓HMG-CoA inhibitors✓✓✓Heparin or antithrombinNO✓✓ClopidogrelNO✓✓GPIIb/IIIa inhibitorsNO✓ (if TIMI ≥3)NOFibrinolytics or PCI^a^NONO✓Cardiology consultOutpatient^b^CCU^c^CCU^ca^for fibrinolytics, the ideal door-to-needle time is \<30 min; for PCI, the ideal door-to-balloon time is \<90 min; urgent CABG is also an option post-catheterization^b^Outpatient cardiology for stress test^c^CCU consult for risk stratification, monitoring, PCI, and/or CABG

**CAUTIONS IN TREATMENT OF ACUTE MYOCARDIAL INFARCTION**---avoid negative inotropic agents such as β-blockers and non-dihydropyridine calcium channel blockers if clinical heart failure. Avoid administration of nitroglycerin, morphine, and diuretics to patients with right ventricular infarction as these medications can cause venodilation and decrease preload, leading to hypotension

Long-Term Management of Coronary Artery Disease {#Sec36}
-----------------------------------------------

**ANTIANGINAL**---**nitroglycerin** (*nitro patch* 0.4--0.8 mg/h daily; nitro spray 0.4 mg SL q5min ×3; *isosorbide mononitrate* 30 mg PO daily, maximum 240 mg), **β-blocker** (*metoprolol* 25--100 mg PO BID, *atenolol* 50--100 mg PO daily, *bisoprolol* 5--10 mg PO daily), **calcium channel blocker** (*amlodipine* 5--10 mg PO daily)

**ACE** **INHIBITOR**---*ramipril* 2.5--10 mg PO daily

**ANTIPLATELET**---***ECASA*** 81 mg PO daily and/or ***clopidogrel*** 75 mg PO daily

**ANTICOAGULATION**---controversial especially in combination with ASA and/or clopidogrel. May be considered for patients post-STEMI or NSTEMI with one of the following criteria: (1) atrial fibrillation, (2) left ventricular thrombus, (3) significant left ventricular dysfunction with extensive regional wall motion abnormalities. Start *warfarin* 5 mg daily within 72 hours and continue heparin/LMWH until INR is between 2 and 3 (unless planning angioplasty)

### Risk Reduction ★Abcdefg★ {#Sec37}

**ASA/ACE** **[inhibitor]{.smallcaps}B** **[lood pressure control]{.smallcaps}** (see HYPERTENSION p. 57)**C** **[holesterol control]{.smallcaps}** (see DYSLIPIDEMIA p. 61)**D** **[iabetic control]{.smallcaps}** (see DIABETES p. 337)**E** **[xercise]{.smallcaps}** (30 min of moderate-intensity exercise 3--4×/week)**F** **[at reduction]{.smallcaps}** (see OBESITY ISSUES p. 403)**G** **[et going to quit smoking!]{.smallcaps}** (see SMOKING ISSUES p. 418)

**DRIVING POST-MYOCARDIAL INFARCTION**---see p. 426 for details

Treatment Issues {#Sec38}
----------------

**RIGHT VENTRICULAR INFARCTION**---evidence of inferior MI should automatically trigger one to check right- sided leads (V4R) to assess for the possibility of RV infarction, which occurs in about 50% of patients with inferior MI. May see increased JVP and clear lungs clinically. ST elevation in V4R is diagnostic and prognostic. Hypotension should be treated with fluid bolus to ensure good preload

**POSTERIOR INFARCTION**---ST depression in V1--V2 in a regular ECG should automatically trigger one to request for posterior (V7--V9) leads to check for posterior MI. Posterior infarct may be associated with inferior infarcts (90%) and lateral infarcts (10%) as the PDA may be supplied by the right or left circumflex coronary artery

### Post-Mi Risk Stratification {#Sec39}

**[extent of infarct/residual function]{.smallcaps}**---assessment is based on clinical factors (↑ HR, ↓ BP, Killip class, diabetes, renal failure, ↑ WBC), ECG, biomarkers (CK, troponin), imaging (echocardiogram, MIBI), and angiography. Early measurement of LV function, although of prognostic importance, is misleading as myocardium function may improve in first 2 weeks. Medical management**[extent of myocardium at risk]{.smallcaps}**---assessment is based on exercise stress test, stress echocardiogram, stress sestamibi (ischemic tissue), thallium scan (viable tissue), PET scan, angiography. Angioplasty or CABG should be considered**[risk of arrhythmia]{.smallcaps}**---high risk of VF/VT within the first 48 h, therefore monitor with telemetry. If it occurs after 48 h, consider antiarrhythmics and early ICD

**BALLOON PUMP**---a long balloon in the descending aorta that deflates during systole and inflates during diastole to augment coronary perfusion and cardiac output as well as decrease afterload. Indicated if cardiogenic shock with hemodynamic instability. May be used in conjunction with inotropes. Contraindicated in aortic regurgitation, AAA, aortic dissection, uncontrolled sepsis bleeding disorder, and severe PVD

**FIBRINOLYTICS USE** **(TPA, SK, RPA, TNK)** **[indications]{.smallcaps}**---≥30 min of chest pain, patient presents within 12 h (ideal door to needle time \<30 min), ECG criteria (\>1 mm ST ↑ in ≥2 contiguous leads, or new LBBB with suggestive history, age \<75)**[absolute contraindications]{.smallcaps}**---any intracranial hemorrhage, ischemic stroke within 3 months, cerebral vascular malformation or brain tumor, closed-head or facial trauma within 3 months, suspected aortic dissection, bleeding diathesis, or active bleeding**[relative contraindications]{.smallcaps}**---severe hypertension (\>180/110 mmHg, may be an absolute contraindication for patients at low risk), ischemic stroke \>3 months, other intracranial diseases not already specified above, dementia, internal bleeding within 2--4 weeks, active peptic ulcer, major surgery within 3 weeks, non-compressible vascular punctures, current warfarin therapy, pregnancy, traumatic CPR \>10 min, prior exposure to streptokinase or anistreplase (if planning to use these fibrinolytics)**[risk of bleeding]{.smallcaps}**---average risk of severe bleed is 1.8%. Increased risk with women, BP \>165/95 mmHg, age \>65, weight \<70 kg \[\<154lbs\], and lysis with TPA (+0.5% absolute risk/factor)**[persistent]{.smallcaps}** **ST** **[elevation]{.smallcaps}**---look for resolution of symptoms and ST elevation to decrease by \>50% within 90 min of fibrinolytic therapy. Persistent ST elevation may suggest failed fibrinolytic therapy, and require urgent rescue catheterization. Other causes of ST elevation include pericarditis, ventricular aneurysm, hyperkalemia, LBBB, and early repolarization abnormality **Related Topics**Aortic Dissection (p. 25)Asystole (p. 431)Diabetes Mellitus (p. 337)ECG (p. 62)Hyperlipidemia (p. 61)Hypertension (p. 57)Pericarditis (p. 32)Shock (p. 97)Smoking Cessation (p. 418)

### Percutaneous Coronary Intervention (Pci, Ptca) {#Sec40}

**[indications for acute]{.smallcaps}** **STEMI**---patient presents within 12 h of chest pain (ideal time from initial medical contact to treatment or "door-to-balloon time" \<90 min), ECG criteria (\>1 mm ST ↑ in ≥2 contiguous leads, new or presumed new left bundle branch block), or in patients in cardiogenic shock within 18 h of infarct**[indications for chronic stable]{.smallcaps}** **CAD**---single/double vessel disease refractory to medical therapy**[adverse events]{.smallcaps}**---access site (bleeding, hematomas, arteriovenous fistulae, pseudoaneurysms), contrast nephropathy, arrhythmia (VT, VF), stroke, dissection, myocardial infarction**[bare metal stents vs. drug-eluting stents]{.smallcaps}**---in-stent restenosis is due to fibrosis of coronary vasculature and usually happens 3 months post-procedure. Drug-eluting stents (sirolimus or paclitaxel) are designed to inhibit cell proliferation and decrease the risk of in-stent restenosis. There has been some controversy regarding higher observed mortality rate in patients with drug-eluting stents. The most recent outcomes research analysis suggests that drug-eluting stents are associated with decreased rate of repeat revascularization (19% vs. 23%, HR 0.82) at 2 years and no significant difference in mortality (8.4% vs. 8.4%)**[benefits]{.smallcaps}**---primary PCI is generally preferred given the superior outcomes compared to fibrinolysis, particularly if (1) fibrinolysis contraindicated, (2) previous history of CABG, or (3) cardiogenic shock. However, patients who were able to seek medical attention within 1 h of chest pain onset, allergic to contrast dye, or do not have access to PCI in a timely fashion should consider fibrinolytics

**OUTCOMES FOR FIBRINOLYTICS VS. PRIMARY PCIFibrinolyticsPrimary PCI**Non-fatal reinfarction7%3%Stroke2%1%Death (4--6 weeks)7--9%5--7%Combined endpoint of death--fatal reinfarction and stroke14%8%**NEJM 2007 356:1; NEJM 2007 356:10; NEJM 357:16**

### Coronary Artery Bypass Graft Surgery {#Sec41}

**CORONARY ANATOMY** **[right coronary]{.smallcaps}** (RCA)---gives rise to right marginal (RMA), right posterior descending (RPDA), and right posterolateral branches (RPL 1, 2, 3)**[left main]{.smallcaps}** (LM)---gives rise to left anterior descending (LAD) → diagonal (D1, 2 3) and septals; ramus intermediate (Ram Int); and left circumflex (LCX) → obtuse marginal (OM 1, 2, 3)**[dominant artery]{.smallcaps}**---defined as the artery that supplies PDA and at least one posterolateral (PL) artery**[indications]{.smallcaps}**---CABG provides mortality benefit for specific subgroups, including patients with (1) left main disease \>50% occlusion, (2) 2 vessel disease with significant involvement of proximal left anterior descending, and (3) diffuse triple vessel disease. Diabetic patients and those with reduced left ventricular function derive more benefit from bypass surgery**[morbidity benefit]{.smallcaps}**---95% have improvement of symptoms immediately after surgery, 75% symptom free at 5 years. Recurrent disease more common in vein grafts than artery grafts**[grafts]{.smallcaps}**---saphenous veins from calf or thigh (SVG), internal mammary arteries (LIMA/RIMA), radial arteries (RA), and gastroepiploic artery from stomach (GA). A total of 90% of arterial graft and 50% of vein graft remain patent by 10 years

**COMPLICATIONS** **[cardiac]{.smallcaps}**---MI 2--4%, arrhythmia (AF 40%, sustained VT/VF 2--3%), AV block requiring pacemaker 0.8--4%, pericarditis/tamponade, aortic dissection**[neurological]{.smallcaps}**---stroke, postoperative delirium, cognitive impairment, depression, phrenic nerve damage, intercostal nerve damage**[others]{.smallcaps}**---renal failure, bleeding, infection, pleural effusions**MEDICATIONS**---hold clopidogrel 5--7 days prior to CABG. Continue ASA before and after surgery

Pericardial Diseases: Pericarditis and Tamponade {#Sec42}
================================================

Differential Diagnosis {#Sec43}
----------------------

### ★MINT★ {#Sec44}

**M** **[etabolic]{.smallcaps}**---uremia, dialysis, hypothyroidism

**M** **[edications]{.smallcaps}**---procainamide, hydralazine, INH, phenytoin, penicillin

**I** **[nfarction]{.smallcaps}**---MI (early, late)

**I** **[nfectious]{.smallcaps}**---HIV, Coxsackie, echovirus, adenovirus, TB

**I** **[nflammatory]{.smallcaps}**---psoriatic arthritis, enteric arthritis, rheumatoid arthritis, SLE, mixed connective tissue disease

Differential Diagnosis (Cont\'d) {#Sec45}
--------------------------------

**I** **[diopathic]{.smallcaps}**

**N** **[eoplastic]{.smallcaps}**---primary (mesothelioma), metastasis (breast, lung, melanoma), leukemia, lymphoma

**T** **[rauma]{.smallcaps}**---stab, gunshot wound, blunt, CPR, post-pericardiotomy

Clinical Features {#Sec46}
-----------------

**RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT WITH A PERICARDIAL EFFUSION HAVE CARDIAC TAMPONADE?SensSpcHistory**Dyspnea87--89%Fever25%Chest pain20%Cough7--10%**Physical**Tachycardia77%Pulsus paradoxus \>10 mmHg^a^82%70%Elevated JVP76%↓ heart sounds28%Hypotension26%Hypertension33%Tachypnea80%Peripheral edema21--28%Pericardial rub19--29%Hepatomegaly28--55%Kussmaul sign26%**ECG**Low voltage42%Atrial arrhythmia6%Electrical alternans16--21%ST elevation18--30%PR depression18%^a^Pulsus paradoxus LR+ 3.3, LR-- 0.03**APPROACH**---"among patients with cardiac tamponade, a minority will not have dyspnea, tachycardia, elevated JVP, or cardiomegaly on chest radiograph. A pulsus paradoxus \>10 mmHg among patients with a pericardial effusion helps distinguish those with cardiac tamponade from those without. Diagnostic certainty of the presence of tamponade requires additional testing"**JAMA 2007 297:16**

**DISTINGUISHING FEATURES OF ACUTE TAMPONADE AND CHRONIC CONSTRICTIVE PERICARDITISAcute tamponadeConstrictive pericarditis**VitalsTachycardia, Hypotension +++, Pulsus paradoxusHypotension, Pulsus paradoxus (rare)JVPElevated, Kussmaul (rare)Prominent *x*' descent but blunted *y* descentElevated, KussmaulProminent *x*' and *y* descent (Friedrich's sign)Apex beatImpalpableImpalpableHeart soundsDistantDistant, early S3/knockOther featuresDullness and bronchial breath sounds over left base (Ewart sign)Hepatosplenomegaly, edema

Investigations {#Sec47}
--------------

### Basic {#Sec48}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, troponin, CK**[imaging]{.smallcaps}**---CXR (calcification if constrictive disease), echocardiogram**ECG**---may have sinus tachycardia, low voltages, and electrical alternans in tamponade/effusion; diffuse ST elevation (concave up) and PR depression may be seen in pericarditis

### Special {#Sec49}

**[pericardiocentesis]{.smallcaps}**---diagnostic or therapeutic (for tamponade, TB/bacterial pericarditis, or large persistent effusion)**[pericardioscopy]{.smallcaps}CT/MRI** **[chest]{.smallcaps}**---if suspect constrictive pericarditis

Management {#Sec50}
----------

**ACUTE PERICARDITIS**---***ASA*** (650 mg PO TID ×3--4 weeks), **NSAIDs** (*indomethacin* 25--50 mg PO TID × 2--4 weeks). Add ***colchicine*** 0.6 mg PO BID ×3 months for adjuvant treatment and long-term prophylaxis. ***Prednisone*** 0.25--0.5 mg/kg PO daily may be used for connective tissue-mediated disease, although symptoms may recur upon withdrawal

**RECURRENT PERICARDITIS**---***ASA*** (650 mg PO TID ×4--8 weeks) or **NSAIDs** (*indomethacin* 25--50 mg PO TID×4--8 weeks). Add ***colchicine*** (0.6 mg PO BID×2 months) for adjuvant treatment and long-term prophylaxis. Avoid anticoagulation as risk of hemopericardium. ***Prednisone*** 0.25--0.5 mg/kg PO daily may also be useful, although symptoms may recur upon withdrawal

**TAMPONADE**---ABC, **O** ~**2**~, IV's, bolus IV fluids, **pericardiocentesis** (subxyphoid blind approach, echocardiogram-guided parasternal or apical approach), **pericardiectomy**, **pericardial window** if recurrent/malignant effusion. Avoid nitroglycerin and morphine if tamponade as they may decrease preload, leading to worsening of cardiac output

**[constrictive pericarditis]{.smallcaps}**---complete pericardiectomy

Specific Entities {#Sec51}
-----------------

**ACUTE PERICARDITIS**---may be preceded by upper respiratory tract infection. Diagnosis is based on any two of the following inflammatory signs (LR+ 5.4): fever, pericardial friction rub (three components), characteristic chest pain (better with upright position and leaning forward, or pleuritic), PR depression, and diffuse ST elevation. Large effusion without inflammatory signs or tamponade suggests chronic idiopathic pericardial effusion (LR+ 20)

**RECURRENT PERICARDITIS**---returns in days to weeks upon stopping medications. Likely causes include rheumatologic disorders, Dressler's syndrome, and post-pericardiotomy syndrome

**TAMPONADE**---a *clinical* diagnosis based on dyspnea, tachycardia, hypotension, pulsus paradoxus, and elevated JVP. Tamponade causes restriction in left or right ventricular diastolic filling. Tamponade with inflammatory signs suggests malignant effusion (LR+ 2.9)

**CONSTRICTIVE PERICARDITIS**---contraction of pericardium due to chronic inflammation, leading to left and/or right heart failure. May follow pericarditis or radiation. May be difficult to distinguish from restrictive cardiomyopathy clinically

Heart Failure {#Sec52}
=============

**NEJM 2003 348:20** **Canadian Heart Failure Guidelines 2006**

Differential Diagnosis of HF Exacerbation/Dyspnea {#Sec53}
-------------------------------------------------

### Cardiac {#Sec54}

**[myocardial]{.smallcaps}**---HF exacerbation, myocardial infarction**[valvular]{.smallcaps}**---aortic stenosis, acute aortic regurgitation, mitral regurgitation/stenosis, endocarditis**[pericardial]{.smallcaps}**---tamponade**[dysrhythmia]{.smallcaps}**

### Respiratory {#Sec55}

**[airway]{.smallcaps}**---COPD exacerbation, asthma exacerbation, acute bronchitis, bronchiectasis, foreign body obstruction**[parenchyma]{.smallcaps}**---pneumonia, cryptogenic organizing pneumonia, ARDS, interstitial lung disease exacerbation**[vascular]{.smallcaps}**---pulmonary embolism, pulmonary hypertension**[pleural]{.smallcaps}**---pneumothorax, pleural effusion

**SYSTEMIC**---sepsis, ARDS, metabolic acidosis, anemia, neuromuscular, psychogenic, anxiety

Pathophysiology {#Sec56}
---------------

### Anatomic/Physiologic Classification of Cardiomyopathy {#Sec57}

**[dilated]{.smallcaps}** (dilatation and impaired contraction of one or both ventricles)---idiopathic, ischemic, valvular, viral, genetic, late manifestation of hypertrophic heart disease, tachycardia induced, alcohol induced, peripartum**[hypertrophic]{.smallcaps}** (disorder with disproportionate hypertrophy of the left ventricle and occasionally right ventricle)---**idiopathic** (autosomal dominant inheritance with incomplete penetrance), **storage** **disease** (Fabry's disease, Pompe disease, Hurler's syndrome, Noonan's syndrome), athlete\'s heart, obesity, amyloid**[restrictive]{.smallcaps}** (non-dilated ventricles with impaired ventricular filling)---idiopathic familial, **infiltrative** (amyloidosis, hemochromatosis, sarcoidosis), drugs, radiation, endomyocardial fibrosis**[arrhythmogenic right ventricular]{.smallcaps}** (replacement of right ventricular free wall with fatty tissue)---arrhythmogenic RV dysplasia**[unclassifiable]{.smallcaps}**---endocardial fibroelastosis, left ventricular non-compaction

### Etiologic Classification of Cardiomyopathy {#Sec58}

**[ischemic cardiomyopathy]{.smallcaps}** (mostly dilated)---varying degrees of persistent ischemia, infarction, and left ventricular remodeling**[valvular cardiomyopathy]{.smallcaps}** (mostly dilated)---abnormal loading conditions and secondary left ventricular remodeling and dysfunction**[hypertensive cardiomyopathy]{.smallcaps}** (dilated, restrictive)---left ventricular hypertrophy and dysfunction**[diabetic cardiomyopathy]{.smallcaps}** (dilated)---left ventricular dysfunction in the absence of atherosclerosis or hypertension**[inflammatory cardiomyopathy]{.smallcaps}** (mostly dilated)---**infectious** (diphtheria, rheumatic fever, scarlet fever, typhoid fever, meningococcal, TB, Lyme disease, Leptospirosis, RMSF, poliomyelitis, influenza, mumps, rubella, rubeola, variola, varicella, EBV, Coxsackie virus, echovirus, CMV, hepatitis, rabies, mycoplasma, psittacosis, arboviruses, histoplasmosis, cryptococcosis, Chagas disease), **autoimmune**, **idiopathic** myocardial inflammatory diseases**[metabolic cardiomyopathy]{.smallcaps}** (dilated, restrictive, and/or hypertrophic)---**endocrine** (thyrotoxicosis, hypothyroidism, acromegaly, pheochromocytoma), **storage diseases** (glycogen storage disease, Fabry's disease, Gaucher's disease, Niemann--Pick disease), **nutritional deficiencies** (Beriberi, Kwashiorkor, pellagra), **deposition** (amyloidosis, hemochromatosis, sarcoidosis)**[muscular dystrophies]{.smallcaps}** (mostly dilated)---Duchenne, Becker's, myotonic dystrophy**[neuromuscular]{.smallcaps}**---Friedreich's ataxia (hypertrophic), Noonan's syndrome, lentiginosis**[general systemic disease]{.smallcaps}** (mostly dilated)---**connective tissue diseases** (rheumatoid heart disease, ankylosing spondylitis, SLE, scleroderma, dermatomyositis), granulomatous (sarcoidosis, Wegener's granulomatosis, granulomatous myocarditis), **other inflammatory** (giant cell myocarditis, hypersensitivity myocarditis), **neoplasm** (primary, secondary, restrictive pattern)**[sensitivity and toxic reactions]{.smallcaps}** (mostly dilated)---alcohol, amphetamine, arsenic, catecholamines, cocaine, anthracyclines, zidovudine, radiation (restrictive as well)**[peripartum]{.smallcaps}** (dilated)---see p. 411

### Functional Classification of Heart Failure {#Sec59}

**[systolic dysfunction]{.smallcaps}** (↓ LVEF \<45%)---S3 (dilated ventricle with volume overload). Mechanisms include decreased contractility and increased afterload. Causes include MI, cardiomyopathy (dilated, infiltrative), valvular (aortic regurgitation, mitral regurgitation, burn out aortic stenosis), burn out hypertension and myocarditis**[diastolic dysfunction]{.smallcaps}** (normal LVEF)---S4 (stiff ventricle), LVH, ↓ ventricular relaxation, normal LVEF, ↑ chamber pressures. Mechanisms include decreased active relaxation and passive relaxation (stiff ventricle). Causes include ischemia, hypertension, valvular (aortic stenosis), cardiomyopathy (restrictive, hypertrophic), and pericardial disease**[mixed dysfunction]{.smallcaps}**---in many cases, diastolic dysfunction is present with systolic heart failure

### precipitants of HF ★FAILURE★ {#Sec60}

**F**orget to take medications (non-adherence)**A**rrhythmia, anemia**I**nfection, ischemia, infarction**L**ifestyle change**U**pregulators (thyroid, pregnancy)**R**heumatic heart disease, acute valvular disease**E**mbolism

Clinical Features {#Sec61}
-----------------

**DISTINGUISHING FEATURES BETWEEN COPD AND HEART FAILURECOPDHeart Failure**HistoryPrevious COPDPrevious HFMedicationsMedicationsInspectNicotine stain, barrel chestLaryngeal height \<4 cmCardiac examSubxyphoid cardiac pulseElevated JVP, S3, S4Resp. examHyperresonanceBilateral cracklesProlonged expiratory timeInvestigationsCXR shows hypeinflationCXR shows redistribution and cardiomegalyABG shows hypercapnia and hypoxemiaABG shows hypoxemiaElevated BNP

**LEFT HEART FAILURE**---left-sided S3, rales, wheezes, tachypnea. Causes include previous MI, aortic stenosis, and left-sided endocarditis

**RIGHT HEART FAILURE**---right-sided S3, ↑ JVP, ascites, hepatomegaly, peripheral edema. Causes include left heart failure, pulmonary hypertension, right ventricular MI, mitral stenosis, and right-sided endocarditis

**GRADING OF PITTING EDEMA**---**0** = no edema, **1** = trace edema, **2** = moderate edema disappears in 10--15 s, **3** = stretched skin, deep edema disappears in 1--2 min, **4** = stretched skin, fluid leaking, very deep edema present after 5 min

### New York Heart Association (Nyha) Classification {#Sec62}

**I** = no symptoms with ordinary physical activity**II** = mild symptoms with normal activity (walking \>2 blocks or 1 flight of stairs)**III** = symptoms with minimal exertion**IV** = symptoms at rest RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS DYSPNEIC PATIENT IN THE EMERGENCY DEPARTMENT HAVE CONGESTIVE HEART FAILURE?**SensSpcLR+LR−History**Initial clinical judgment61%80%4.40.45Hx heart failure60%90%5.80.45Myocardial infarction disease40%87%3.10.69Coronary artery52%70%1.80.68Dyslipidemia23%87%1.70.89Diabetes28%83%1.70.86Hypertension60%56%1.40.71Smoker62%27%0.841.4COPD34%57%0.811.1PND41%83%2.60.70Orthopnea50%77%2.20.65Edema51%76%2.10.64Dyspnea on exertion84%34%1.30.48Fatigue and weight gain31%70%1.00.99Cough36%61%0.931.0**Physical**S313%99%110.88AJR24%96%6.40.79JVD39%92%5.10.66Rales60%78%2.80.51Any murmur27%90%2.60.81Lower extremity edema50%78%2.30.64Valsalva maneuver73%65%2.10.41SBP \<100 mmHg6%97%2.00.97S45%97%1.60.98SBP ≥150 mmHg28%73%1.00.99Wheezing22%58%0.521.3Ascites1%97%0.331.0**CXR**Pulmonary venous congestion54%96%120.48Interstitial edema34%97%120.68Alveolar edema6%99%6.00.95Cardiomegaly74%78%3.30.33Pleural effusions26%92%3.20.81Any edema70%77%3.10.38Pneumonia4%92%0.501.0Hyperinflation3%92%0.381.1**ECG**Atrial fibrillation26%93%3.80.79New Twave changes24%92%3.00.83Any abnormal finding50%78%2.20.64ST elevation5%97%1.80.98ST depression11%94%1.70.95**BNP**BNP ≥100 pg/mL4.10.09For patients with an estimated GFR of 15--60 mL/min/1.73 m^2^, a threshold of 201 pg/mL can be used**APPROACH**---"the features evaluated in more than one study with the highest LRs (\>3.5) for diagnosing heart failure were the following: the overall clinical judgment, history of heart failure, S3, jugular venous distension, pulmonary venous congestion or interstitial edema on CXR, and atrial fibrillation on ECG. The features evaluated in more than one study with the lowest LRs (\<0.60) for diagnosing of heart failure were the following: the overall clinical judgment, no prior history of heart failure, no dyspnea on exertion, the absence of rales, and the absence of radiographic pulmonary venous congestion, or cardiomegaly. The single finding that decreased the likelihood of heart failure the most was a BNP \<100 pg/mL. While the findings of this study are useful when assessing dyspneic patients suspected of having heart failure, no individual feature is sufficiently powerful in isolation to rule heart failure in or out. Therefore, an overall clinical impression based on all available information is best. If the appropriate constellation of findings with high LRs for heart failure are present, that may be sufficient to warrant empirical treatment without further urgent investigations"**JAMA 2005 294:15**

### Rational Clinical Examination Series: Does This Patient Have Abnormal Central Venous Pressure? {#Sec63}

**JVP** **VS. CAROTID**---JVP has biphasic waveforms, is non-palpable, is occludable, decreases with inspiration, changes with position, and increases with abdominojugular reflux (AJR). To perform the AJR, the blood pressure cuff is pumped 6× and then pressed against the abdomen at 20--35 mmHg for 15--30 s. Normal = no change in JVP, or transient increase of \>4 cm that returns to baseline before 10 s, or sustained increase \<3 cm throughout. Positive AJR occurs when abdominal compression causes a sustained increase in JVP \>4 cm (sens 24%, spc 96%, LR+ 6.4)

**APPROACH**---"once the JVP is identified, measure the vertical height. A distance ≥4 cm above the sternal angle is considered abnormal (i.e. CVP ≥9cmH~2~O). An assessment of low JVP has an LR+ for low CVP of 3.4, while an assessment of high JVP has an LR+ for high CVP of 4.1"

**JAMA 1996 275:8**

### Rational Clinical Examination Series: Can The Clinical Examination Diagnose Left-Sided Heart Failure In Adults? {#Sec64}

**INCREASED FILLING PRESSURE**---very helpful findings are **radiographic redistribution** and **jugular venous distension**. Somewhat helpful findings are dyspnea, orthopnea, tachycardia, decreased systolic or pulse pressure, S3, rales, and abdominojugular reflux. Edema is helpful only when present

**SYSTOLIC DYSFUNCTION**---very helpful findings are **radiograph** (cardiomegaly, redistribution), **anterior Q waves**, **LBBB**, and **abnormal apical impulse** (especially if sustained). Somewhat helpful findings are tachycardia, decreased blood pressure or pulse pressure, S3, rales, dyspnea, previous infarction other than anterior, and high peak CK (post-infarct). Edema and increased jugular venous pressure are helpful if present

**DIASTOLIC DYSFUNCTION**---very helpful finding is **elevated blood pressure** during the episode of increased filling pressure. Somewhat helpful findings are obesity, lack of tachycardia, older age, and

absence of smoking or CAD. Normal radiographic heart size is helpful if present

**APPROACH**---"in patients without known systolic dysfunction, ≤1 finding of increased filling pressure can exclude diagnosis, ≥3 findings suggests increased filling pressure. In patients with known systolic dysfunction, absence of finding of increased filling pressure can exclude diagnosis, ≥1 finding suggests increased filling pressure. For systolic dysfunction, can exclude diagnosis if no abnormal findings, including no sign of increased filling pressure are present (LR-- 0.1). ≥3 findings are needed to confirm the diagnosis (LR+ 14)"

**JAMA 1997 277:21**

Investigations {#Sec65}
--------------

### Basic {#Sec66}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, troponin/CK ×3, BNP, D-dimer, TSH, albumin**[imaging]{.smallcaps}**---CXR, echocardiogram (check E/A ratio if diastolic dysfunction)**ECG**

### Special {#Sec67}

**[further imaging]{.smallcaps}**---MIBI, MUGA**[stress test]{.smallcaps}**---to assess ischemic heart disease**[cardiac catheterization]{.smallcaps}ABG**---if severe dyspnea

Diagnostic and Prognostic Issues {#Sec68}
--------------------------------

### B-Type Natriuretic Peptide {#Sec69}

**[diagnosis]{.smallcaps}**---in addition to heart failure, BNP is also elevated with PE, pulmonary hypertension, LVH, ACS, AF, renal failure, overload, and sepsis **BNPHeart Failure diagnosis**\<100 pg/mLUnlikely100--250 pg/mLCompensated LV dysfunction250--500 pg/mLHF with both diastolic andsystolic dysfunction500--1000 pg/mLDecompensated HF\>1000 pg/mLHigh risk of substantial HF**[prognosis]{.smallcaps}**---BNP \>80^th^ percentile is associated with a \>50% increase in long-term mortality

**HF** **PROGNOSIS**---33% 1-year mortality, 75% 6-year mortality

Acute Management {#Sec70}
----------------

**ABC**---O~2~ to keep sat \>95%, IV's

**[symptom control]{.smallcaps}**---★**LMNOP**★ ***L*** *asix/furosemide* 20--100 mg IV PRN, ***M*** *orphine* 2--5 mg IV PRN, ***N*** *itroglycerin* 0.4 mg SL PRN, **O** ~2~, **P**osition (upright)

Long-Term Management {#Sec71}
--------------------

### ★DDDD★ {#Sec72}

**DIET**---**low salt** (\<100 mmol/day, 1.5--2 g/day), **fluid** **restriction** (1.5--2 L/day)

**DIURETICS**---***furosemide*** 20--100 IV/PO daily-BID with daily adjustments (try to use smallest dose possible to allow ACE inhibitor) ± ***metolazone*** 2.5--5 mg PO 30 min before furosemide, ***spironolactone*** 12.5--50 mg PO daily or ***eplerenone*** 25--50 mg PO daily

**VASODILATORS**---**ACE inhibitor** (*captopril* 6.25--50 mg PO TID, *enalapril* 2.5--20 mg PO BID, *ramipril* 2.5--10 mg PO daily, *lisinopril* 2.5--20 mg PO daily, *perindopril* 2--8 mg PO daily). **ARB** (*valsartan* 40--160 mg PO BID, *candesartan* 8--32 mg PO daily). ***Hydralazine*** 10 mg PO QID and *nitropatch* 0.4 mg PO daily. **β-blockers** (*metoprolol* 50--100 mg PO BID, *carvedilol* 3.125--25 mg PO BID, *bisoprolol* 2.5--10 mg PO daily)

**DIGITALIS**---***digoxin*** 0.125--0.25 mg PO daily

**[treat underlying cause]{.smallcaps}**---**CAD** (CABG), **aortic** **stenosis** (AV replacement), **sleep apnea** (CPAP)

**DEVICES**---if ejection fraction \<30--35%, consider **cardiac resynchronization therapy** (CRT/biventricular pacing) ± **implantable cardioerter defibrillators** (ICD). **Ventricular assist devices** may also be considered in selected cases of refractory HF

Treatment Issues {#Sec73}
----------------

**ACE** **INHIBITOR** (Garg, JAMA 1995)---hazard ratios for total mortality 0.77 and mortality/hospitalization 0.65 for any patients with LVEF \<40%. Target dose = maximum tolerated. Contraindications include SBP \<80 mmHg, bilateral renal artery stenosis, severe renal failure, and hyperkalemia

**ARB** (Jong, J Am Coll Cardiol 2002, CHARM)---consider substitution with ARB if ACE inhibitor *not tolerated* (e.g. cough). May also be used as adjunct to ACE inhibitor if β-blocker not tolerated. Contraindications similar to ACE inhibitor

**HYDRALAZINE/NITRATES** (VHEFT I and II, A-HeFT)---less effective than ACE inhibitor. Particularly useful for pregnant patients, African Americans, or those who developed renal insufficiency while on ACE inhibitor, or as add-on therapy

**β-BLOCKERS** (Foody JAMA 2002)---hazard ratios for total mortality 0.65 and mortality/hospitalization 0.64. May worsen symptoms in first few weeks and may take up to 1 year to see full effect in LVEF. Useful for patients with NYHA II--III (and stable IV) and LVEF \<40%, also NYHA I, LVEF \<40%, and post-MI. Contraindications include fluid overload and severe asthma. Start only when patient euvolemic

**SPIRONOLACTONE** (RALES 1999, EPHESUS 2003)---hazard ratios for total mortality 0.7 and mortality/hospitalization 0.65. For patients with NYHA III--IV, LVEF \<35%, and on maximum treatment already. Caution in elderly and renal failure patients as higher risk of hyperkalemia

**DIGOXIN** (DIG 1997)---hazard ratios for total mortality 0.99 and mortality/hospitalization 0.92. Particularly useful for patients with both HF and atrial fibrillation, or symptomatic HF despite maximum treatment

**OVERALL APPROACH**---treat underlying cause if possible. Non-pharmacological treatments (diet, exercise, smoking cessation) → add ACE inhibitor for all (or hydralazine/nitrates if renal failure, ARB if cough secondary to ACE inhibitor) → add β-blocker when euvolemic → add spironolactone/eplerenone if NYHA III/IV → add digoxin ± ARB if still symptomatic. If ejection fraction is \<30--35% despite optimal medical therapy, consider revascularization, implantable cardioverter defibrillator, cardiac resynchronization (if QRS is wide), and ventricular-assist device/heart transplant

Specific Entities {#Sec74}
-----------------

**[causes of flash pulmonary edema]{.smallcaps}**---**cardiac** (ischemic heart disease, acute aortic regurgitation, acute mitral regurgitation, mitral stenosis/obstruction, arrhythmia), **pulmonary** (pulmonary embolism, pneumonia), **renal** (bilateral renal artery stenosis), **systemic** (hypertension crisis, fever, sepsis, anemia, thyroid disease)

### Hypertrophic Obstructive Cardiomyopathy (HOCM) {#Sec75}

**[pathophysiology]{.smallcaps}**---autosomal dominant condition with mutated cardiac sarcomere, leading to massive ventricular hypertrophy (particularly septum). This results in left ventricular outflow tract obstruction, mitral regurgitation, diastolic dysfunction, and subsequently myocardial ischemia and overt heart failure. Cardiac arrhythmias may lead to sudden death (\<1%/year). Other complications include atrial fibrillation and infective endocarditis**[risk factors]{.smallcaps}** **[for sudden death]{.smallcaps}**---major risk factors include history of cardiac arrest (VF), sustained VT, unexplained syncope, non-sustained VT on Holter, abnormal BP response on exercise test, left ventricular wall thickness \>30 mm, and family history of sudden death. Minor risk factors include left ventricular outflow obstruction (gradient ≥30 mmHg), microvascular obstruction, and high-risk genetic defect**[clinical features]{.smallcaps}**---most are asymptomatic although dyspnea, chest pain, syncope, and sudden death may develop. Family history should be obtained. Physical findings include brisk carotid upstroke, bifid carotid pulse, double apical impulse, systolic ejection murmur (LLSB, louder with standing and Valsalva) ± mitral regurgitation murmur**[diagnosis]{.smallcaps}**---echocardiogram (septal thickening, systolic-anterior motion of mitral valve). Further workup includes 48 h holter monitor and exercise testing annually**[treatments]{.smallcaps}**---**avoidance** (dehydration and strenuous exercise), **medical** (β-blockers and non-dihydropyridine calcium channel blockers as first line, disopyramide as second line), **interventional/surgical** (septal myomectomy, alcohol septal ablation, dual-chamber pacing), **prophylaxis** (implantable cardioverter defibrillator for high-risk patients to prevent sudden cardiac death, anticoagulation if atrial fibrillation)

**NEJM 2004 350:13**

Digoxin Intoxication {#Sec76}
====================

**Circulation 2004 109:24**

Differential Diagnosis {#Sec77}
----------------------

**[overdose]{.smallcaps}**---intentional, accidental (digoxin, foxglove, yellow oleander)

**DRUG INTERACTIONS**---quinidine, amiodarone, verapamil, diltiazem, tetracycline, erythromycin, rifampin, cyclosporine, SSRIs

### Pharmacokinetics {#Sec78}

**[old age, renal failure]{.smallcaps}[cardiac]{.smallcaps}**---ischemia, myocarditis, cardiomyopathy, amyloidosis, cor pulmonale**[metabolic]{.smallcaps}**---hypokalemia, hypomagnesemia, hypernatremia, hypercalcemia, hypoxemia, acid-base imbalance

Pathophysiology {#Sec79}
---------------

**DIGOXIN LEVEL**---measurement of serum levels is not routinely necessary as dosing can usually be titrated according to clinical and hemodynamic effects. When measured, serum level should be collected at 12--24 h after the last dose (post-distribution phase). While the upper normal limit is 2.6 nmol/L \[2.0 ng/mL\], higher digoxin levels may be seen in asymptomatic patients. Low-dose digoxin, resulting in serum levels 0.5--0.9 nmol/L \[0.4--0.7 ng/mL\] is associated with possible survival benefit compared to ≥1 nmol/L \[≥0.78 ng/mL\] in HF patients

**MECHANISM**---digitalis acts by inhibiting the membrane-bound Na/K ATPase transport system. This leads to intracellular loss of K and gain of Na. Increase in intracellular Ca leads to ↑ cardiac contractility. Digoxin also exerts a vagotonic action, which slows conduction through the SA and AV node and helps to control heart rate

**PRECIPITANTS OF DIGOXIN TOXICITY**---toxicity is not merely related to serum levels, but also digoxin dosing (e.g. acute overdose), other medications (e.g. non-potassium sparing diuretics), and conditions (e.g. renal insufficiency, acute coronary syndromes, cardiac amyloidosis, hypothyroidism). For instance, hypokalemia, hypernatremia, hypomagnesemia and acidosis predispose to toxicity even at low-serum digoxin levels because of their depressive effects on the Na/K ATPase pump. In contrast, hyperkalemia occurs in acute toxicity and is directly related to prognosis

Clinical Features {#Sec80}
-----------------

### Signs and Symptoms {#Sec81}

**[neurological]{.smallcaps}**---delirium, hallucination, blurred vision with altered color perception, headaches, dizziness**[cardiac]{.smallcaps}**---bradycardia, high-degree AV block, paroxysmal atrial tachycardia, unifocal or multifocal PVCs, bidirectional ventricular tachycardia, accelerated junctional tachycardia**GI**---anorexia, N&V, diarrhea, abdominal pain**[metabolic]{.smallcaps}**---hyperkalemia

Investigations {#Sec82}
--------------

### Basic {#Sec83}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, Ca, Mg, albumin, serum digoxin level**ECGABG**

Diagnostic Issues {#Sec84}
-----------------

### Ecg Changes Associated with Digoxin {#Sec85}

**[therapeutic levels]{.smallcaps}**---sagging of ST segments, flattened T waves, U waves, and shortened QT. Not to be confused with digoxin toxicity**[toxic levels]{.smallcaps}**---first degree heart block, paroxysmal atrial tachycardia, regularized atrial fibrillation, unifocal or multifocal PVCs, ventricular bigeminy, bidirectional VT

Management {#Sec86}
----------

**ACUTE**---ABC, **O** ~**2**~, IV, **TREAT ARRHYTHMIA**

**[treat underlying cause]{.smallcaps}**---**observe, cardiac monitoring, activated charcoal** (if ingestion within 4 h). **Correct** electrolyte disturbances and reverse acidosis. **Atropine** for bradycardia. **Digibind/purified antidigoxin FAB fragments** (if ingested 10 mg of more in adults, or digoxin level \>13 nmol/L \[10 ng/mL\], K \>5 mM and life-threatening arrhythmia, hemodynamic instability or severe bradycardia. May see response in 20 min and complete response up to 4 h. Monitor potassium levels after treatment with Digibind)

Treatment Issues {#Sec87}
----------------

### Avoid {#Sec88}

**IV** **[calcium]{.smallcaps}**---indicated for other causes of severe hyperkalemia, calcium may precipitate VT/sudden death and should **NOT** be given for hyperkalemia of digoxin toxicity**[cardioversion]{.smallcaps}**---relatively contraindicated because asystole or ventricular fibrillation may be precipitated**[transvenous pacing]{.smallcaps}**---can precipitate arrhythmias and deterioration

**HALF-LIVES**---plasma *t* ~½~ for digoxin 1.6 days, digitoxin 5 days

**INDICATIONS FOR DIGOXIN THERAPY**---in patients with **symptomatic systolic HF and sinus rhythm** (digoxin may be especially useful in patients with severe symptoms despite standard medical therapy, LVEF \<25%, or cardiomegaly), **diastolic HF** (with rapid atrial fibrillation or severe symptoms despite standard medical therapy), and **rapid atrial fibrillation** (with or without heart failure). Use with extreme caution or avoid in the elderly, patients with severe conduction abnormalities, acute coronary syndromes, or renal failure

Atrial Fibrillation {#Sec89}
===================

**NEJM 2001 344:14; NEJM 2004 351:23**

Differential Diagnosis of Palpitations {#Sec90}
--------------------------------------

### ★PPP★ {#Sec91}

**P** **[hysiologic]{.smallcaps}** (high output states)---anemia, pregnancy, fever, exercise, stress

**P** **[athologic ★cde★]{.smallcaps}**

**C** **[ardiac]{.smallcaps}**---**arrhythmia** (see tachycardia below), **myocardial** (cardiomyopathy, atrial myxoma, shunts), valvular, transplanted heart**D** **[rugs]{.smallcaps}**---sympathomimetic agents, vasodilators, anticholinergic agents, β-blocker withdrawal, illicit (cocaine, amphetamines)**E** **[ndocrine]{.smallcaps}**---hypoglycemia, hyperthyroidism, pheochromocytoma

**P** **[sychiatric]{.smallcaps}**---panic attack/disorder, generalized anxiety disorder, somatization

Differential Diagnosis of Narrow Complex Tachycardia {#Sec92}
----------------------------------------------------

**REGULAR NARROW COMPLEX TACHYCARDIA**---sinus tachycardia, atrial flutter with fixed block (rate 300, 150, 100, 75, 60), supraventricular tachycardia (atrial tachycardia, AV nodal reentry, AV reentrant/WPW), accelerated junctional tachycardia

**IRREGULAR NARROW COMPLEX TACHYCARDIA**---sinus tachycardia/arrhythmia, premature atrial contractions, multifocal atrial tachycardia, atrial flutter with variable block, atrial fibrillation

Differential Diagnosis of Irregularly Irregular Rhythm {#Sec93}
------------------------------------------------------

**ATRIAL**---sinus arrhythmia (rate 60--100), wandering pacemaker (rate 60--100), premature atrial rhythm/beat, multifocal atrial tachycardia (rate \>100), ectopic atrial tachyarrhythmia with variable block, atrial flutter with variable block, atrial fibrillation

**VENTRICULAR**---premature ventricular contraction, polymorphic ventricular tachycardia, ventricular fibrillation

Pathophysiology {#Sec94}
---------------

### Causes of Atrial Fibrillation {#Sec95}

**[cardiovascular]{.smallcaps}**---**myocardial** (hypertension, CAD, HF, hypertrophic cardiomyopathy, dilated cardiomyopathy, myocarditis, infiltration \[amyloidosis, sarcoidosis, hemochromatosis\], ASD), **valvular** (rheumatic, acquired, endocarditis), **arrhythmia** (WPW, SSS), **pericardial** (pericarditis), cardiac surgery**[pulmonary]{.smallcaps}**---COPD, pulmonary embolism, pleural effusion

Pathophysiology (Cont\'d) {#Sec96}
-------------------------

**[metabolic]{.smallcaps}**---thyrotoxicosis, obesity**[drugs]{.smallcaps}**---theophylline, adenosine, digitalis, β-agonists, alcohol**[idiopathic]{.smallcaps}** (10%)

### Classification of Atrial Fibrillation {#Sec97}

**[paroxysmal atrial fibrillation]{.smallcaps}**---episodes of AF last \<7 days (usually \<24 h). Self-terminating**[persistent atrial fibrillation]{.smallcaps}**---lasts longer than 7 days and fails to self-terminate (i.e. requires cardioversion)**[permanent atrial fibrillation]{.smallcaps}**---arrhythmia lasts longer than 1 year; unable to cardiovert**[lone atrial fibrillation]{.smallcaps}**---atrial fibrillation in patients \<60 years, no structural heart disease or risk factors, including hypertension

Clinical Features of Narrow Complex Tachycardia {#Sec98}
-----------------------------------------------

**HISTORY**---palpitations, chest pain, dyspnea, dizziness, syncope, past medical history (AF, SVT, WPW, CAD, HF, hypertension, diabetes, stroke, TIA, thyroid dysfunction), medications (antihypertensives, antiarrhythmics), DVT/PE risk factors

**PHYSICAL**---vitals (pulse rate and rhythm, blood pressure), cardiac and pulmonary examination for heart failure

**CAROTID SINUS MASSAGE, VALSALVA, OR ADENOSINE**---SVT may spontaneously terminate, while AF or atrial flutter may slow down. Avoid adenosine if suspect WPW

Clinical Features {#Sec99}
-----------------

RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT WITH PALPITATIONS HAVE A CARDIAC ARRHYTHMIA?**Any arrhythmiaSignificant arrhythmiaLR+LR−LR+LR−History**Cardiac disease2.030.710.421.07Male sex1.630.761.200.90Age \>601.700.831.890.77Smoking \>11/day0.781.030.771.03Anxiety disorder0.981.010.921.04FH of palpitations0.861.041.070.98EtOH \>10 days/week0.761.051.021.00Panic disorder0.261.30----Any psychiatric disorders----0.671.12**Palpitations**Regular1.66--1.380.55Irregular1.650.62--1.23Duration \>5 min1.520.380.790.95Duration \>60 s1.150.691.170.63Continuous symp1.06--0.931.20HR \>100/min0.91--1.080.86**Precipitating factors**Affected by sleep2.290.702.440.63Occurring at work2.170.761.540.86Caffeine1.840.912.060.89Occurs holiday1.560.920.791.04Occurs weekend1.430.900.721.08Alcohol1.360.961.940.90Lying in bed1.300.611.020.97Exercise0.741.090.781.07Breathing0.521.230.521.20While resting----1.020.97**Associated symptoms**Regular rapid pounding sensation in neck----1770.07Neck fullness----0.851.04Visible neck pulsations----2.680.87Dizzy spells0.931.081.340.67Chest pain0.811.070.921.02Dyspnea0.31--0.271.12Vasovagal symp----1.720.63Presyncope----1.040.95**Physical examination**HR \<60 or \>100----3.000.78Obesity----1.550.93Hypertension----1.011.00**APPROACH**---"while the presence of a regular rapid-pounding sensation in the neck or visible neck pulsations associated with palpitations makes the diagnosis of atrioventricular nodal reentry tachycardia likely, the reviewed studies suggest that the clinical examination is not sufficiently accurate to exclude clinically significant arrhythmias in most patients. Thus, prolonged electrocardiographic monitoring with demonstration of symptom-rhythm correlation is required to make the diagnosis of a cardiac arrhythmia for most patients with recurrent palpitations"**JAMA 2009 302:19**

Investigations {#Sec100}
--------------

### Basic {#Sec101}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, TSH, INR, PTT**[imaging]{.smallcaps}**---CXR, echocardiogram (enlarged left atrium)**ECG[24-hour holter]{.smallcaps}[exercise stress test]{.smallcaps}**

### Special {#Sec102}

**ELECTROPHYSIOLOGY STUDIES**

Acute Management {#Sec103}
----------------

**ABC**---**O** ~**2**~ to keep sat \>95%, IV

**SYNCHRONIZED CARDIOVERSION**---premedicate if possible with *midazolam* 1--2 mg IV q2--3 min, *fentanyl* 50--150  μg IV ×1, shock 50, 100, 200, 300, 360 J, prepare to intubate and give IV anti-arrhythmics PRN

### AV nodal blocking agents ★ABCD★ {#Sec104}

**A** **[miodarone]{.smallcaps}**---*amiodarone* 150 mg IV bolus over 10 min, q10--15 min. Alternatively, infusion 60 mg/h over 6 hours, then 30 mg/h over 18 h. Maximum 2.2 g/day**[β-blockers]{.smallcaps}**---*esmolol* 500 μg/kg IV over 1 min, maintenance dose 50--200 μg/kg/min IV, *metoprolol* 5 mg IV over 1 min q5min ×3 PRN**C** **[alcium channel blockers]{.smallcaps}**---*diltiazem* 15--20 mg IV over 2 min, repeat in 15 min at 20--25 mg PRN, maintenance dose 5--20 mg/h IV; *verapamil* 2.5--5.0 mg IV over 1--2 minutes, followed by 5--10 mg in 15--30 minutes PRN with maximum of 30 mg, maintenance dose 0.05--0.2 mg/min IV**D** **[igitalis]{.smallcaps}**---*digoxin* 0.25--0.5 mg IV q6h to a total dose of 1 mg, maintenance dose 0.125--0.25 mg PO/IV daily

### Overall Approach {#Sec105}

**[unstable atrial fibrillation]{.smallcaps}**---perform cardioversion immediately**[stable atrial fibrillation \<48 hour]{.smallcaps}**---**rate control** (β-blockers, calcium channel blockers, digoxin) and consider **rhythm control** (DC cardioversion, amiodarone, propafenone, flecainide). Need to be anticoagulated for 4 weeks post-cardioversion**[stable atrial fibrillation \>48 hour or unknown duration]{.smallcaps}**---**rate control** (β-blockers, calcium channel blockers, digoxin) and consider **rhythm control** (IV heparin → TEE to exclude atrial thrombus → cardioversion within 24 h → anticoagulate ×4 weeks; ALTERNATIVELY anticoagulate ×3 weeks → cardioversion → anticoagulate ×4 weeks)**[treat underlying cause/precipitant]{.smallcaps}**---infection, myocardial infarction, ischemia, drugs, pulmonary embolism, thyrotoxicosis

Long-Term Management {#Sec106}
--------------------

**RATE CONTROL**---aim for a resting heart rate \<80 and exercise heart rate \<110. **β-blocker** (*propranolol* 10--30 mg PO TID--QID, *metoprolol* 50--100 mg PO BID). **Calcium channel blockers** (*diltiazem CD* 120--480 mg PO daily). **Digitalis** (*digoxin* 0.5 mg PO ×1 dose, then 0.25 mg ×2 doses q6--12 h, then 0.125--0.25 mg daily)

**RHYTHM CONTROL**---**elective cardioversion** (only after a 3-week course of therapeutic anticoagulation or atrial thrombus excluded by TEE. Cardioversion should be followed by 4 weeks of anticoagulation). **Antiarrhythmics** (*amiodarone* 200--400 mg PO daily, *sotalol* 80--160 mg PO BID, especially if CAD; *flecainide* 50 mg PO q12h, especially if no structural heart disease; *propafenone* 150 mg PO q8h, especially if no structural heart disease)

**CLOT CONTROL**---***ASA*** 81 mg daily if no other risk factors (see CHADS2). Otherwise, ***warfarin*** 5 mg PO daily within 72 hours and continue heparin until INR is between 2 and 3. Heparin is not required if no thrombosis

**PROCEDURES**---**radiofrequency ablation** of the pulmonary veins (PVI). Radiofrequency ablation of AV node with insertion of a permanent pacemaker and long-term anticoagulation as last resort. **Surgical** (corridor and maze procedures)

Treatment Issues {#Sec107}
----------------

### Stroke Risk Factors in Patients with Atrial Fibrillation ★Chads2★ {#Sec108}

**CHF** (any history, 1 point)**H** **[ypertension]{.smallcaps}** (any history, 1 point)**A** **[ge]{.smallcaps}** \>75 (1 point)**D** **[iabetes]{.smallcaps}** (1 point)**S** **[troke or]{.smallcaps}** **TIA** (2 points) **RISK OF STROKE**---0 points=0.49%/year (lone AF), 1=1.5%, 2=2.5%, 3=5.3%, 4=6.0%, 5--6=6.9%**[other risk factors]{.smallcaps}**---CAD, echocardiography abnormalities (atrial size \>5 cm, LV dysfunction), rheumatic valve disease (RR 17). *All* mitral stenosis and HOCM patients with AF should have chronic anticoagulation**RISK REDUCTION**---anticoagulation decreases risk of stroke by ∼60% (consider warfarin if CHADS2 score ≥1). ASA decreases risk by ∼30%**[risk of bleeding on anticoagulation]{.smallcaps}**---1.9% per year of major bleed. Thus, only recommend anticoagulation if risk of stroke ≥1.5% (i.e. at least one risk factor)

**FACTORS INCREASING RISK OF BLEED WITH WARFARIN USE**---advanced age (3--4% risk of significant bleeding per year if age \>80), recent hemorrhage, uncontrolled hypertension, alcohol binge drinking or liver disease, cancer, renal insufficiency, low platelets, ASA/clopidogrel/NSAIDs (including COX-2 inhibitors). Note that risk of fall by itself is not a contraindication to warfarin use. Warfarin is teratogenic and should be avoided in pregnancy

### Important Toxicities of Amiodarone {#Sec109}

**[cardiac]{.smallcaps}** (5%)---sinus bradycardia and AV nodal block. QT prolongation leading to torsade de pointes may rarely occur**[thyroid]{.smallcaps}**---causes of hyperthyroidism (3%) include amiodarone-induced thyroiditis and Jod-Basedow phenomenon (excess iodine with amiodarone allows increased synthesis of T4 in patients with pre-existing toxic nodules). Patients on amiodarone may not develop classic symptoms of hyperthyroidism; however, recurrence of AF should prompt investigations. Hypothyroidism is more common (20%)**[pulmonary]{.smallcaps}** (\<3%)---chronic interstitial pneumonitis (most common), cryptogenic organizing pneumonia, ARDS, and solitary pulmonary nodule. Histologically characterized by foamy macrophages in the air space. DLCO is often decreased. CT chest may show diffuse/localized interstitial or alveolar opacities. Treat with steroids and stop amiodarone**[hepatic]{.smallcaps}** (15%)---non-alcoholic steatohepatitis which in severe cases may lead to cirrhosis**[neurologic]{.smallcaps}** (30%)---ataxia, tremor, peripheral polyneuropathy, insomnia, and impaired memory**[vision]{.smallcaps}** (100%)---corneal microdeposits may result in halo vision, photophobia, and blurred vision. Optic nerve injury (1--2%) may cause blindness**[dermatologic]{.smallcaps}** (25--75%)---photosensitivity, gray-bluish discoloration (blue man syndrome), and alopecia. This is reversible upon discontinuation of amiodarone, but may take a few years**[monitoring]{.smallcaps}**---baseline TSH, LFTs, PFT and CXR. TSH and LFTs every 6 months, CXR yearly, and PFT as needed

**NEJM 2007 356:9** **Related Topics**ACLS (p. 431)Digoxin (p. 38)ECG (p. 62)Wolff--Parkinson--White Syndrome (p. 65)

Syncope {#Sec110}
=======

See SYNCOPE (p. 312)

Cardiac Examination {#Sec111}
===================

Pulse {#Sec112}
-----

**PULSUS TARDUS ET PARVUS** (low carotid upstroke and amplitude)---aortic stenosis

**BRISK PULSE** (rapid carotid upstroke)---hypertrophic cardiomyopathy

**BOUNDING PULSE** (rapid carotid upstroke and descent)---↑ left ventricular volume (aortic regurgitation, mitral regurgitation, VSD, PDA, severe bradycardia), ↓ peripheral resistance (fever, anemia, thyrotoxicosis, rigid arteries)

**[pulsus bisferiens]{.smallcaps}** (double-peaked)---combination aortic stenosis and regurgitation

**REGULARLY IRREGULAR PULSE**---sinus arrhythmia, pulsus bigeminus (PVC, PAC)

**IRREGULARLY IRREGULAR PULSE**---atrial fibrillation, premature atrial or ventricular contractions

Blood Pressure {#Sec113}
--------------

**CORRECT CUFF SIZE**---width of bladder ≥40% of arm circumference or length of bladder ≥80% of arm circumference

**AUSCULTATORY GAP**---defined as the gap between the first Korotkoff sound (which may disappear briefly) and its reappearance. Missing the higher reading can lead to an underestimation of systolic blood pressure. Thus, the systolic blood pressure should always be palpated first before auscultation

**WIDE PULSE PRESSURE**---isolated systolic hypertension, aortic regurgitation, hyperdynamic states (sympathetic hyperactivity, fever/sepsis, anemia, thyrotoxicosis, large AV fistula, PDA, beriberi)

**PSEUDOHYPERTENSION**---false elevation of systolic blood pressure secondary to rigid arteries. The Osler's maneuver may be useful for determining the presence of pseudohypertension

**PULSUS ALTERNANS** (alternating fluctuation in pulse pressure)---initially hear only the more prominent beats. As cuff pressure decreases, start to hear the less intense beats (1:1 ratio). This may be detected in severe LV dysfunction and aortic stenosis

**PULSUS PARADOXUS**---inspiratory drop in systolic blood pressure \>10 mmHg. Causes include asthma, COPD, **tamponade**, restrictive cardiomyopathy, constrictive pericarditis, hypovolemic shock, and rarely pulmonary embolism, SVC obstruction, and morbid obesity

Jugular Venous Pressure {#Sec114}
-----------------------

**A WAVE**---atrial contraction**[prominent a wave]{.smallcaps}**---tricuspid stenosis, pulmonary stenosis, pulmonary hypertension, hypertrophic cardiomyopathy, and Ebstein\'s anomaly**[cannon a wave]{.smallcaps}**---complete heart block, ventricular tachycardia (right atrium contracts against closed tricuspid valve)**[decreased a wave]{.smallcaps}**---dilated right atrium**[absent a wave]{.smallcaps}**---atrial fibrillation

**X DESCENT**---atrial relaxation. S1 starts**[decreased x descent]{.smallcaps}**---atrial fibrillation**[x descent deeper than y descent]{.smallcaps}**---tamponade

**C WAVE**---bulging of tricuspid valve into right atrium during ventricular isometric contraction

**X\' DESCENT**---descent of the base of the heart during systole

**V WAVE**---atrial filling. S2 just before peak of v**[dominant v wave]{.smallcaps}**---tricuspid regurgitation (cv wave), right heart failure, atrial septal defect

**Y DESCENT**---opening of tricuspid valve/atrial emptying**[rapid steep y descent]{.smallcaps}**---constrictive pericarditis (square root sign), severe right heart failure**[decreased y descent]{.smallcaps}**---tricuspid stenosis**[blunted/absent y descent]{.smallcaps}**---tamponade

**ABDOMINOJUGULAR REFLUX** **(AJR)**---blood pressure cuff pumped 6x, then pressed against abdomen at 20--35 mmHg for 15--30 s. Positive AJR occurs when abdominal compression causes a sustained increase in JVP \>4 cm \[\>1.6 in.\] and predicts elevated left atrial pressure (≥15 mmHg, LR+ 8.0, LR-- 0.3)

**[kussmaul's sign]{.smallcaps}**---paradoxical increase in JVP during inspiration. Causes include right ventricular failure, restrictive cardiomyopathy, constrictive pericarditis, SVC obstruction, and pulmonary embolism

Precordial Examination {#Sec115}
----------------------

**INSPECTION**---apex, right ventricular heave

**PALPATION**---apex, heaves, thrills, palpable heart sounds**[displaced apical beat]{.smallcaps}** (lateral to mid-clavicular line)---left ventricular dilatation, LR+ 8.0**[enlarged apical beat]{.smallcaps}** (≥2.5 cm)---left ventricular dilatation, LR+ 4.7**[sustained apical beat]{.smallcaps}** (outward impulse extends to, or past, S2)---left ventricular pressure overload (aortic stenosis), volume overload (aortic regurgitation, VSD), severe cardiomyopathy, or ventricular aneurysm**[retracting apical beat]{.smallcaps}** (retraction during systole; inward motion begins at S1, outward impuse after S2)---constrictive pericarditis (up to 90%), tricuspid regurgitation**[sustained left parasternal movement]{.smallcaps}** ("lift/heave")---tricuspid regurgitation, mitral regurgitation**[palpable]{.smallcaps}** **P2**---pulmonary hypertension in mitral stenosis, LR+ 3.6

Heart Sounds {#Sec116}
------------

**TECHNIQUE**---S1, S2, and physiological splitting of S2 are best heard over the base. Identification of S3 and S4 requires conscious effort listening for low-pitched sounds over the apex (using the bell)

**DISTINGUISHING** **S1** **[from]{.smallcaps}** **S2**---time with carotid pulse, diastole longer than systole, S2 louder than S1 at the base, S1 is low pitched and longer while S2 is high pitched and shorter, S2 is usually split

### Intensity of S1 And S2 {#Sec117}

**[loud]{.smallcaps}** **P2** **[\>]{.smallcaps}** **A2** **[at pulmonic area]{.smallcaps}**---increased pulmonary pressure (left ventricular failure, mitral stenosis, pulmonary hypertension), increased pulmonary flow (atrial septal defect)**[loud]{.smallcaps}** **S2** **[at aortic area]{.smallcaps}**---**hypertension**, **hyperdynamic states** (fever, hyperthyroidism, anemia)**[soft]{.smallcaps}** **S2** **[over aortic area]{.smallcaps}**---severe aortic stenosis**[loud]{.smallcaps}** **S1** **[at mitral area]{.smallcaps}**---mitral stenosis**[soft]{.smallcaps}** **S1**---mitral regurgitation, left bundle branch block, short PR interval

### Splitting of S2 {#Sec118}

**[fixed splitting]{.smallcaps}** (splitting same degree during both inspiration and expiration)---atrial septal defect, right ventricular failure**[wide splitting]{.smallcaps}** (splitting greater during inspiration than expiration)---right bundle branch block, pulmonary stenosis, pulmonary hypertension**[paradoxical (reversed) splitting]{.smallcaps}** (splitting only during expiration)---left bundle branch block, severe aortic stenosis, RV pacing **EXTRA HEART SOUNDSSoundHeardPitchOthers**S1LUSBHighEarly systolic clickRUSBHighAortic stenosisMid-systolic clickApexHighMVP, louder standingS2LUSBHighSplittingOpening snap (early diastolic)ApexHighMitral stenosisS3 (early diastolic)ApexLowHeart failureS4 (late diastolic)ApexLowHTN, aortic stenosis

High pitch sounds are best heard with the diaphragm, while low pitch sounds are best heard with the bell

### Distinguishing Features Between P2 and Opening Snap {#Sec119}

P2 is best heard at LUSB while opening snap is best heard at the apexP2 separates from A2 on inspiration, while opening snap tends to move closer to S2 on inspiration

**[distinguishing features between]{.smallcaps}** **S4** **[and]{.smallcaps}** **S1** S4 is usually best heart at apex with the bell while S1 is best heard at baseS4 is usually more widely separated from S1 than splitting of S1S4 is loudest at the start of expiration, softest at mid-inspirationS4 may be accentuated by lying down, exercise, or forced inspiration with closed glottisS4 has a lower pitch than S1

### Distinguishing Features Between S3 and Opening Snap {#Sec120}

S3 has a lower pitch than opening snapS3 occurs later than opening snap

### Distinguishing Features Between S3 and S4 {#Sec121}

S3 has a lower pitch than S4S3 is closer to S2 while S4 is closer to S1Left ventricular S3 is louder at the apex while right ventricular S3 or S4 is usually best heart at left sternal border or at the base

Murmurs {#Sec122}
-------

### Timing {#Sec123}

**[mid-systolic]{.smallcaps}**---aortic stenosis, aortic sclerosis, pulmonary stenosis, hypertrophic obstructive cardiomyopathy, atrial septal defect, flow murmurs (fever, pregnancy, hyperthyroidism, anemia, aortic regurgitation due to high flow)**[pansystolic]{.smallcaps}**---mitral regurgitation, tricuspid regurgitation, ventricular septal defect, aortopulmonary shunts**[late systolic]{.smallcaps}**---mitral valve prolapse, papillary muscle dysfunction**[early diastolic]{.smallcaps}**---aortic regurgitation, pulmonary regurgitation**[mid-diastolic]{.smallcaps}**---mitral stenosis, tricuspid stenosis, atrial myxoma, Austin Flint murmur of aortic regurgitation, Carey Coombs murmur of RHD**[pre-systolic]{.smallcaps}**---mitral stenosis, tricuspid stenosis, atrial myxoma**[continuous murmurs]{.smallcaps}**---patent ductus arteriosus, arteriovenous fistula, aortopulmonary connection, venous hum, mammary souffle

**[intensity]{.smallcaps}**---grade I (barely audible), grade II (faint but can be heard immediately), grade III (easily heard), grade IV (loud AND associated with palpable thrill), grade V (very loud, can be heard with the stethoscope half off chest), grade VI (very loud, can be heard with stethoscope off chest wall)

**[quality]{.smallcaps}**---depends on the pitch, may be musical, harsh, blowing, rumbling, scratchy, grunting, or squeaky

**[configuration]{.smallcaps}**---crescendo, decrescendo, crescendo--decrescendo, plateau, holosystolic

**[location]{.smallcaps}**---aortic valve (RUSB), pulmonary valve (LUSB), tricuspid valve (LLSB), mitral valve (apex)

**[radiation]{.smallcaps}**---aortic valve (carotids), pulmonary valve (left shoulder), tricuspid valve (xyphoid, right of sternum), mitral valve (axilla)

### Maneuvers {#Sec124}

**[respiration]{.smallcaps}**---**right-sided** murmurs typically increase with inspiration (except pulmonic click) or sustained abdominal pressure (↑ venous return), while **left-sided** murmurs are generally louder during expiration**V** **[alsalva maneuver]{.smallcaps}** (↓ venous return and ↑ systemic arterial resistance)---most murmurs decrease in length and intensity during the Valsalva maneuver. Two exceptions are the systolic murmur of **hypertrophic cardiomyopathy**, which usually becomes much louder, and the systolic murmur of **mitral valve prolapse**, which becomes longer and often louder (click moves closer to S1)**[positional changes]{.smallcaps}**---most murmurs diminish with standing due to reduced preload. However, the murmur of **hypertrophic cardiomyopathy** becomes louder and the murmur of **mitral valve prolapse** lengthens and often is intensified. Squatting (or usually passive leg raising, both ↑ venous return and ↑ systemic arterial resistance) produces opposite effect**[isometric exercise]{.smallcaps}** (↑ systemic arterial resistance)---murmurs caused by blood flow across normal or obstructed valves (e.g. **mitral or pulmonic stenosis**) become louder. Murmurs of **mitral and aortic regurgitation** and **ventricular septal defect** also increase with handgrip exercise**[transient arterial occlusion]{.smallcaps}** (↑ systemic arterial resistance)---transient external compression of both arms by bilateral cuff inflation to 20 mmHg greater than peak systolic pressure augments the murmurs of **mitral regurgitation, aortic regurgitation, and ventricular septal defect**, but not murmurs due to other causes ![](186923_3_En_2_Figa_HTML.gif){#d29e7077}

### Rational Clinical Examination Series: Does This Patient Have an Abnormal Systolic Murmur? {#Sec125}

**AORTIC STENOSIS**---"presence of any of following significantly increases the likelihood of aortic stenosis: effort syncope, slow carotid upstroke, late or mid peaking systolic murmur, decreased or absent S2, apical-carotid delay, brachioradial delay. The absence of any systolic murmur or murmur radiation to the right carotid artery reduces the likelihood of aortic stenosis"

**MITRAL REGURGITATION**---"for cardiologists, absence of a mitral area murmur or a late systolic/holosystolic murmur significantly reduces the likelihood of mitral regurgitation, except in the setting of acute MI. Cardiologists can accurately distinguish left-sided regurgitant murmurs, such as mitral regurgitation and ventricular septal defect, using transient arterial occlusion"

**TRICUSPID REGURGITATION**---"cardiologists can accurately detect the murmur of tricuspid regurgitation. Cardiologists can accurately rule in and rule out tricuspid regurgitation using the quiet inspiration and sustained abdominal pressure maneuvers"

**HYPERTROPHIC CARDIOMYOPATHY**---"cardiologists can rule in or rule out hypertrophic cardiomyopathy by evaluating for decreased murmur intensity with passive leg elevation or increased murmur intensity when the patient goes from a **squatting to standing position**"

Murmurs (cont\'d) {#Sec126}
-----------------

**MITRAL VALVE PROLAPSE**---"a **systolic click, with or without systolic murmur**, is sufficient for the diagnosis of mitral valve prolapse. The absence of both a systolic click and murmur significantly reduces the likelihood of echocardiographic mitral valve prolapse. In patients with echocardiographic mitral valve prolapse, a holosystolic murmur without a systolic click significantly increases the likelihood of long term complications, whereas absence of both a systolic click and murmur significantly reduces the likelihood of long term complications"

**JAMA 1997 277:7**

###  {#Sec127}

**INNOCENT MURMURS**---in otherwise healthy younger patients. Systolic murmurs tend to be mid-systolic, grade 1 or 2 (possibly 3), loudest over LUSB, and do not radiate. Diastolic murmurs are always abnormal

### Rational Clinical Examination Series: Does This Patient Have Aortic Regurgitation? {#Sec128}

**AORTIC REGURGITATION**---"when a cardiologist hears the typical murmur of aortic regurgitation,

Murmurs (cont\'d) {#Sec129}
-----------------

the likelihood of mild or greater aortic regurgitation is increased significantly. The absence of a typical **diastolic murmur** significantly reduces the likelihood of aortic regurgitation"

**MITRAL STENOSIS**---"presence of a **mid-diastolic murmur** significantly increases the likelihood of mitral stenosis, while absence of a mid-diastolic murmur significantly reduces the likelihood of mitral stenosis"

**PULMONARY rEGURGITATION**---"when a cardiologist hears a typical pulmonary regurgitation murmur, the likelihood of pulmonary regurgitation increases significantly. Absence of a typical murmur does not alter the likelihood of pulmonary regurgitation"

**JAMA 1999 281:23**

Investigations {#Sec130}
--------------

**[echocardiogram]{.smallcaps}**---if cardiac symptoms, murmur grade ≥3, diastolic murmur, or when other cardiac findings are present

Aortic Stenosis {#Sec131}
===============

**ACC/AHA 2008 Guidelines** **Lancet 2009 373:9667; NEJM 2002 346:9**

Differential Diagnosis {#Sec132}
----------------------

### Valvular {#Sec133}

**[congenital malformations]{.smallcaps}**---unicuspid, bicuspid, tricuspid**[calcification]{.smallcaps}**---degenerative or senile, atherosclerosis, Paget\'s disease, chronic renal failure**[infections]{.smallcaps}**---rheumatic fever, *Chlamydia pneumoniae***[rheumatoid arthritis]{.smallcaps}**

**SUBVALVULAR**

**[discrete lesions]{.smallcaps}**---membranous diaphragm, fibromuscular ring**[obstructive]{.smallcaps}**---hypertrophic cardiomyopathy

**SUPRAVALVULAR**---localized or discrete narrowing of the ascending aorta (Williams\' syndrome)

**LOW GRADIENT AORTIC STENOSIS**---resulting from low cardiac output

Pathophysiology {#Sec134}
---------------

### Complications ★BEE★ {#Sec135}

**B**leeding (angiodysplasia + aortic stenosis + acquired vWD type IIa = Hedye's syndrome)**E**ndocarditis**E**mbolic events (cerebral, systemic)

Clinical Features {#Sec136}
-----------------

**PHYSICAL**---tachypnea, decreased pulse pressure, brachioradial delay, pulsus parvus et tardus (slow rise and low amplitude), apical-carotid delay, hyperdynamic apical beat, systolic thrill at the base of heart, narrowly split or paradoxical splitting of S2 or absent S2, harsh mid-systolic ejection murmur (radiation to carotids), Gallavardin phenomenon

**G** **[allavardin phenomenon]{.smallcaps}**---aortic stenosis murmur is usually harsh and loudest over the right upper sternal border, whereas a Gallavardin murmur is musical and may be heard over apex. It is due to radiation of the high-frequency components of the aortic stenosis murmur to the apex **DISTINGUISHING FEATURES BETWEEN AORTIC SCLEROSIS AND AORTIC STENOSIS MURMURAortic sclerosisAortic stenosis**PathophysiologyAbnormally thickened valve leaflets but minimal outflow obstructionDecreased functional area of valve to cause decreased outflowCarotid pulseNormalPulsus parvus et tardusS2NormalSoft single S2 (P2)MurmurMid-systolic murmurLate peaking of systolic murmur DISTINGUISHING FEATURES BETWEEN AORTIC STENOSIS, MITRAL REGURGITATION, AND HYPERTROPHIC CARDIOMYOPATHY**Aortic StenosisMitral RegurgitationHOCM**Carotid upstrokeSlow, low amplitudeNormal or low amplitudeBriskS1NormalSoftNormalS2Single if severeNormalOften reversedS3NoLoudNoS4If severeNoYesLoudest murmurRUSBApexLLSB and apexManeuvers    Standing↓↓↑    Squatting↑↑↓    Valsalva↓↓↑

Investigations {#Sec137}
--------------

### Basic {#Sec138}

**CXR[echocardiogram]{.smallcaps}**---transthoracic**ECG**---left ventricular hypertrophy**[exercise testing]{.smallcaps}**

### Special {#Sec139}

**[cardiac catheterization]{.smallcaps}**

Diagnostic and Prognostic Issues {#Sec140}
--------------------------------

### Aortic Valve Area and Severity {#Sec141}

**[normal]{.smallcaps}** = 3--4 cm^2^**[mild]{.smallcaps}** = 1.5--2 cm^2^ or mean gradient \<25 mmHg**[moderate]{.smallcaps}** = 1--1.5 cm^2^ or mean gradient 25--40 mmHg**[severe]{.smallcaps}** = \<1 cm^2^ or mean gradient \>40 mmHg**[symptoms]{.smallcaps}**---usually do not appear until valve \<1 cm^2^. The significance of valve area depends on patient size (larger patient = more severe for same valve area)**[progression]{.smallcaps}**---valve area decreases by ∼0.1 cm^2^/year and the mean gradient increases by 7 mmHg/year (particularly if cardiac risk factors)

**PROGNOSIS OF AORTIC STENOSIS** ★**ASH**★ (**A**ngina, **S**yncope, **H**eart failure)**[severe aortic stenosis with no symptoms]{.smallcaps}**---1--2% die in short period**[severe aortic stenosis with angina presentation]{.smallcaps}**---50% die in 5 years**[severe aortic stenosis with syncope presentation]{.smallcaps}**---50% die in 3 years**[severe aortic stenosis with heart failure presentation]{.smallcaps}**---50% die in 2 years**[severe aortic stenosis after valve replacement]{.smallcaps}**---survival similar to normal individuals

Management {#Sec142}
----------

**MILD OR MODERATE AORTIC STENOSIS**---follow clinically and with echocardiogram (every 3--5 years for mild, every 1--2 years for moderate, every year for severe). Statins may slow progression with early aortic stenosis

**SEVERE OR SYMPTOMATIC AORTIC STENOSIS**---**aortic valve replacement** (see criteria below), balloon valvuloplasty (offers no survival benefit and is only a temporizing measure)

**VASODILATORS**---use with caution in the setting of hypertension or HF. ACE inhibitors preferred over β-blockers because of risk of reduced inotropy; start low dose and titrate slowly; risk of hypotension and syncope

Treatment Issues {#Sec143}
----------------

### Aortic Valve Replacement (AVR) {#Sec144}

**[absolute indications]{.smallcaps}**---severe aortic stenosis with any classic symptoms (angina, syncope, dyspnea) or with LV dysfunction, severe aortic stenosis and require CABG/surgery of aorta/other heart valves**[possible indications]{.smallcaps}**---moderate aortic stenosis and require CABG/surgery of aorta/other heart valves, asymptomatic severe aortic stenosis and one of hemodynamic instability during exercise, or ventricular tachycardia**[preoperative consult]{.smallcaps}**---AVR should be done before elective non-cardiac surgeries in symptomatic patients**[risk of]{.smallcaps}** **AVR**---mortality 1--2%, morbidity 1%/year (venous thromboembolic disease, bleeding, deterioration of prosthetic valve, endocarditis)

**MECHANICAL VS. BIOPROSTHETIC VALVE**---compared to human tissue valves, mechanical valves have prolonged durability, but higher chance of thromboembolism and bleeding from chronic anticoagulation. Overall, long-term outcomes are better with a mechanical valve. Main indications for bioprosthesis valve include patients who cannot or will not tolerate warfarin or for whom compliance is uncertain, patients ≥65 years of age who do not have risk factors for thromboembolism, and women of childbearing age

Aortic Regurgitation {#Sec145}
====================

**ACC/AHA 2008 Guidelines**

Differential Diagnosis {#Sec146}
----------------------

**VALVE ABNORMALITY**---rheumatic heart disease, infective endocarditis, SLE, calcifications, congenital (bicuspid or unicuspid aortic valve), flail leaflet, osteogenesis imperfecta, drugs (fenfluramine)

**AORTIC DILATION**---aortic dissection, ankylosing spondylitis, syphilis, Marfan's, Ehlers Danlos, hypertension, bicuspid aortic valve, cystic medial necrosis

Pathophysiology {#Sec147}
---------------

**PATHOPHYSIOLOGY**---leaky aortic valve → initial compensation with left ventricular dilatation and eccentric hypertrophy (palpitations, atypical chest pain), wide pulse pressure (due to increased stroke volume with elevation in systolic blood pressure and regurgitation with rapid collapse of the arteries and a low diastolic blood pressure) → eventually decompensation leading to left ventricular dysfunction (heart failure)

Clinical Features {#Sec148}
-----------------

### Physical {#Sec149}

**[general appearance]{.smallcaps}**---Marfan's syndrome, ankylosing spondylitis, Argyll Robertson pupils, **Quincke\'s pulses** (capillary pulsations in the fingertips or lips), digital throb, **Becker\'s sign** (visible pulsations of the retinal arteries and pupils), **deMusset\'s sign** (head bob occurring with each heart beat), **Mueller\'s sign** (systolic pulsations of the uvula)**[vitals]{.smallcaps}**---wide pulse pressure, **water hammer** (tapping impulse in forearm, especially when arm is raised vertically), **Corrigan\'s pulse, Mayne\'s sign** (\>15 mmHg decrease in diastolic blood pressure with arm elevation)**[cardiac]{.smallcaps}**---soft S1, left-sided S3 (heart failure), **diastolic murmur** (early diastolic or holodiastolic, blowing, over left upper sternal border), **Austin Flint murmur** (mid/late diastolic rumble, over apex) and **mid-systolic flow murmur[others]{.smallcaps}**---**Gerhard\'s sign** (systolic pulsations of the spleen), **Rosenbach\'s sign** (systolic pulsations of the liver), **Traube\'s sign** (pistol shot pulse with systolic and diastolic sounds heard over the femoral arteries), **Duroziez\'s sign** (systolic and diastolic bruit heard when the femoral artery is partially compressed), **Hill\'s sign** (popliteal cuff systolic pressure exceeding brachial pressure by \>60 mmHg). Note that all the special signs are due to increased pulse pressure

### Distinguishing Features Between Aortic Regurgitation And Pulmonary Regurgitation Murmur {#Sec150}

**[pulmonary regurgitation murmur]{.smallcaps}**---high pitch decrescendo diastolic murmur (Graham Steell murmur) loudest over **left upper sternal border**. **Increases with inspiration**. May be associated with signs of pulmonary hypertension**[aortic regurgitation murmur]{.smallcaps}**---early diastolic decrescendo murmur loudest over **right and/or left upper sternal border**. No change or decreases with inspiration. May be associated with **Austin Flint murmur** and the other signs of aortic regurgitation **DISTINGUISHING FEATURES BETWEEN AUSTIN FLINT AND MITRAL STENOSIS MURMURAustin FlintMitral stenosis**GenderM \>FF \>MHemoptysisAlmost neverLikely mitral stenosisRhythmSinusAtrial fibrillationM1Usually faintUsually loudP2Normal or ↑Usually loudVentricular gallop/S3Always presentAbsentDiastolic murmurUsually early or mid-diastolicOften presystolic accentuation (if in sinus rhythm)Opening snapAbsentPresentCXRBoot shapedLAEECGSinus, LVH, Prolonged PRAtrial fibrillation, P mitrale

Investigations {#Sec151}
--------------

### Basic {#Sec152}

**CXR**---cardiomegaly**[echocardiogram]{.smallcaps}ECG**---LVH**[exercise testing]{.smallcaps}**

### Special {#Sec153}

**[cardiac catheterization]{.smallcaps}**

Prognostic Issues {#Sec154}
-----------------

### Asymptomatic with Normal Lv Systolic Function {#Sec155}

**[prognosis]{.smallcaps}**---development of symptoms and/or LV dysfunction \<6%/year; asymptomatic LV dysfunction \<3.5%/year; sudden death \<0.2%/year

### Asymptomatic with Lv Dysfunction {#Sec156}

**[prognosis]{.smallcaps}**---progression to cardiac symptoms \>25%/year

### Symptomatic {#Sec157}

**[prognosis]{.smallcaps}**---mortality \>10%/year

Management {#Sec158}
----------

**[lifestyle changes]{.smallcaps}**---salt restriction/diuretics

**MEDICATIONS**---afterload reduction with vasodilators (hydralazine, nifedipine, ACE inhibitors) indicated for severe AR with symptoms, LV dysfunction, or LV dilatation, but not for long-term management of asymptomatic mild to moderate AR and normal LV function.

**FOLLOW-UP**---asymptomatic mild AR with normal LV function and little/no LV dilatation can be followed annually with echocardiogram every 2--3 years (sooner if symptoms emerge). Asymptomatic severe AR with normal LV function and LV dilatation (\>60 mm) should be seen every 6 months with echocardiogram every 2--3 years

**PROCEDURES**---**aortic valve replacement** if symptomatic; asymptomatic with end-systolic dimension \>55 mm, end-diastolic dimension \>75 mm, ejection fraction \<50%; or asymptomatic severe aortic regurgitation at time of concomitant cardiac surgery. Intra-aortic balloon pumps should not be used

**ANTIBIOTIC PROPHYLAXIS**---not typically indicated unless aortic valve replacement or previous endocarditis

Mitral Stenosis {#Sec159}
===============

**ACC/AHA 2008 Guidelines; Circulation 2009 119:11**

Differential Diagnosis {#Sec160}
----------------------

**RHEUMATIC HEART DISEASE**

**MITRAL ANNULAR CALCIFICATION**

**CONGENITAL**

**ENDOCARDITIS**

**ATRIAL MYXOMA**

**PROSTHETIC VALVE DYSFUNCTION**

Pathophysiology {#Sec161}
---------------

**STENOTIC MITRAL VALVE**---left ventricular inlet obstruction → left atrial overload and left ventricle output failure → atrial fibrillation, pulmonary hypertension and eventually right heart failure

**VALVE AREA**---normal 4--5 cm^2^, mild symptoms 1.5--2 cm^2^ (mean gradient \<5 mmHg), moderate symptoms 1--1.5 cm^2^ (mean gradient 5--10 mmHg), severe symptoms \<1 cm^2^ (mean gradient \>10 mmHg)

Clinical Features {#Sec162}
-----------------

**HISTORY**---symptoms related to pulmonary hypertension (dyspnea, hemoptysis, chest pain), symptoms related to right heart failure (hepatomegaly, ascites, edema), hoarseness (Ortner\'s syndrome, due to enlarged left atrium compressing on recurrent laryngeal nerve), complications (endocarditis, thromboembolism), past medical history (rheumatic fever), medications

### Physical {#Sec163}

**[general appearance]{.smallcaps}**---tachypnea, peripheral cyanosis, mitral facies (purple patches on cheeks secondary to vasoconstriction)**[vitals]{.smallcaps}**---decreased pulse volume**[jvp]{.smallcaps}**---prominent a wave (pulmonary hypertension), absent a wave (atrial fibrillation), cv wave (tricuspid regurgitation)**[cardiac]{.smallcaps}**---right ventricular heave, palpable P2 (pulmonary hypertension), loud S1 (valve cusps widely apart at the onset of systole), loud S2, absent S3, opening snap (over apex and left lower sternal border. The earlier the opening snap, the more severe the stenosis), low pitch diastolic rumble (over apex, left decubitus position in expiration) ± pre-systolic accentuation, tricuspid regurgitation**[abdominal]{.smallcaps}**---hepatomegaly, ascites, edema

Investigations {#Sec164}
--------------

### Basic {#Sec165}

**CXR**---left atrial enlargement, splaying of carina**[echocardiogram]{.smallcaps}**---TEE to exclude left atrial thrombus before treatment**ECG**---P mitrale, RVH

### Special {#Sec166}

**[cardiac catheterization]{.smallcaps}**

Diagnostic and Prognostic Issues {#Sec167}
--------------------------------

**MITRAL VALVE AREA AND SEVERITY** **[normal]{.smallcaps}** = 4--5 cm^2^**[mild]{.smallcaps}** = 1.5--2.5 cm^2^ or mean gradient \<5 mmHg**[moderate]{.smallcaps}** = 1--1.5 cm^2^ or mean gradient 5--10 mmHg**[severe]{.smallcaps}** = \<1 cm^2^ or mean gradient \>10 mmHg**[symptoms]{.smallcaps}**---usually do not appear until valve \<2.0 cm^2^. Symptoms at rest appear when valve \<1.5 cm^2^. Onset of symptoms usually precipitated by exercise, emotional stress, infection, pregnancy, or rapid atrial fibrillation

**PROGRESSION**---∼0.1--0.3 cm^2^/year. Initially slow stable course (latent period) of 20--40 years between rheumatic fever and symptoms. From onset of symptoms (accelerated period), around 10 years until disability. Overall 10-year survival is 50--60% in untreated symptomatic MS, \>80% in asymptomatic. Median survival \<3 years with severe pulmonary hypertension

Management {#Sec168}
----------

**LIFESTYLE CHANGES**---salt restriction/diuretics

**MEDICATIONS**---negative chronotropic agents to prolong diastolic filling (β-blockers, non-dihydropyridine calcium channel blockers). Anticoagulation for patients with concomitant atrial fibrillation, left atrial thrombus, or prior embolic event (even if in sinus rhythm). Prophylaxis for rheumatic fever (secondary prevention)

**FOLLOW-UP**---any change in symptoms warrant re-evaluation and echocardiogram. Otherwise, yearly evaluation in asymptomatic patients including CXR and ECG. Yearly echocardiogram for severe MS

**PROCEDURES**---indicated when symptomatic severe mitral stenosis. **Percutaneous balloon mitral valvuloplasty** (particularly for patients with non-calcified mitral valve, mild mitral regurgitation, and no other cardiac interventions) is equivalent to **surgical valvuloplasty** in terms of success. Average increase in valve area is 1.0 cm^2^

Specific Entities {#Sec169}
-----------------

### Acute Rheumatic Fever and Rheumatic Heart Disease {#Sec170}

**[pathophysiology]{.smallcaps}**---group A *Streptococcus* infection → non-suppurative inflammation with cardiac, joints, and CNS manifestations 2--4 weeks later. Post-*Streptococcus* glomerulonephritis and scarlet fever may also occur separately as complications of group A *Streptococcus* infection**[jones criteria for acute rheumatic fever]{.smallcaps}** **[major criteria]{.smallcaps}** ★**J♡NES**★**J** **[oint-migratory polyarthritis]{.smallcaps}♡** **[carditis]{.smallcaps}** (pericarditis, myocarditis, valvulitis)**N** **[odules]{.smallcaps}** (subcutaneous)**E** **[rythema marginatum]{.smallcaps}S** **[ydenham chorea]{.smallcaps}[minor criteria]{.smallcaps}**---clinical (fever, polyarthralgias), laboratory (↑ ESR, prolonged PR interval)**[diagnosis]{.smallcaps}**---either two major criteria or one major criterion and two minor criteria, **plus** evidence of antecedent streptococcal infection (e.g. positive throat culture or rapid antigen detection test or elevated streptococcal antibody test)**[investigations]{.smallcaps}**---anti-Streptolysin O antibodies, anti-DNase B, antihyaluronidase, positive throat culture, echocardiogram**[treatments]{.smallcaps}**---patients with rheumatic disease are at high risk of recurrent rheumatic fever. Recurrent disease causes additional valve damage, and thus these patients should receive prophylaxis for rheumatic fever (*penicillin G* 1.2 M U IM q4weeks, *penicillin V* 250 mg PO BID, or *erythromycin* 250 mg PO BID if allergic to penicillin). For patients with valve involvement, therapy should continue for at least 10 years after the last episode of rheumatic fever and to at least age 40. With a history of carditis in the absence of persistent valvular disease, treat for 10 years or until age 21 (whichever is longer)

Mitral Regurgitation {#Sec171}
====================

**ACC/AHA 2008 Guidelines**

Differential Diagnosis {#Sec172}
----------------------

**VALVE ABNORMALITY**---rheumatic heart disease, infective endocarditis, mitral valve prolapse, myxomatous degeneration, mitral annular calcification, ruptured chordae tendineae, drugs (fenfluramine)

**LEFT VENTRICULAR DILATATION**---myocardial infarction, dilated cardiomyopathy

Pathophysiology {#Sec173}
---------------

**LEAKY MITRAL VALVE**---left atrial and ventricle volume overload → atrial fibrillation and left heart failure

Clinical Features {#Sec174}
-----------------

**CLINICAL FEATURES**---exertional dyspnea, fatigue, decreased S1, widely split S2, S3, holosystolic murmur (over apex), displaced apex

Investigations {#Sec175}
--------------

### Basic {#Sec176}

**CXR**---cardiomegaly, LAE**[echocardiogram]{.smallcaps}ECG**---P mitrale, LVH

### Special {#Sec177}

**[cardiac catheterization]{.smallcaps}**

Management {#Sec178}
----------

**MEDICATIONS**---no specific therapy for MR. Treat concomitant atrial fibrillation if present

**FOLLOW-UP**---asymptomatic mild MR with normal LV function and no LV dilatation can be followed annually. Asymptomatic severe MR should be seen every 6--12 months with echocardiogram at the time of assessment

**PROCEDURES**---**mitral valve repair** (generally better outcome if technically possible) or **replacement** if symptomatic, atrial fibrillation, pulmonary hypertension, end-systolic dimension \>40 mm, or ejection fraction 30--60%

Specific Entities {#Sec179}
-----------------

### Tricuspid Regurgitation {#Sec180}

**[pathophysiology]{.smallcaps}**---leaky tricuspid valve → right atrium and ventricle volume overload → eventually decompensation leading to right heart failure (hepatosplenomegaly, ascites, peripheral edema)**[causes]{.smallcaps}**---right ventricular dilatation (left heart failure, pulmonary hypertension, Eisenmenger syndrome, pulmonic stenosis), valve abnormality (rheumatic heart disease, infective endocarditis, Ebstein's anomaly). Rarely is it due to isolated tricuspid valve abnormality**[clinical features]{.smallcaps}**---cachexia, jaundice, JVP cv wave, RV heave, S3 (with dilated RV), S4 (with stiff RV), holosystolic murmur (over left lower sternal border), hepatomegaly, edema**[investigations]{.smallcaps}**---ECG (P pulmonale, RVH), CXR (cardiomegaly), echocardiogram, cardiac catheterization, rule out intracardiac shunts**[treatments]{.smallcaps}**---valve repair or replacement if severe symptoms

### Mitral Valve Prolapse {#Sec181}

**[pathophysiology]{.smallcaps}**---autosomal dominant inherited connective tissue disorder with morphologic abnormalities of the mitral valve (increased leaflet thickness and redundancy, chordal elongation, and sagging of the leaflets into the left atrium in systole)**[treatments]{.smallcaps}**---*ASA* 75--325 mg PO daily for history of transient ischemic attacks, atrial fibrillation (age \<65 years, no MR, no HTN, no HF). Anticoagulation with warfarin for atrial fibrillation (if age \>65, MR, HTN, or HF), history of stroke/TIA, or left atrial thrombus **TWO SUBTYPES OF MITRAL VALUE PROLAPSEMild subtypeSevere subtype**DemographicsMainly women (age 20--50)Mainly men (age 40--70)PathologyMild leaflet abnormalitiesMinimal MRMyxomatous diseaseConsiderable leaflet thickening and MRSymptomsOrthostatic hypotensionPalpitationsAtrial fibrillationPhysical findingsMid-systolic click with or without a late systolic murmurMR murmurChordal rupture may lead to sudden worsening of MRPrognosisFew patients have progressive MRProgressive MR requiring surgeryIncreased risk of sudden death

Endocarditis {#Sec182}
============

**NEJM 2001 345:18**

Differential Diagnosis {#Sec183}
----------------------

### Infective Endocarditis {#Sec184}

**[common]{.smallcaps}**---*Streptococcus viridans* (*S. sanguis*, *S. mutans*, *S. mitis*), *Streptococcus pneumoniae*, *Streptococcus bovis*, *Enterococcus* (*E. faecalis*, *E. faecium*), *Staphylococcus aureus*, Gram-negative bacilli**[long incubation time (7--21) days]{.smallcaps}** ★**HACEK**★***H*** *aemophilus****A*** *ctinobacillus****C*** *ardiobacterium****E*** *ikenella****K*** *ingella***[special media]{.smallcaps}**---*Mycoplasma*, *Chlamydia*, *Legionella*, *Brucella*, *Bartonella*, *Coxiella burnetii* (Q fever), *Histoplasma*, *Tropheryma whippelii*

**MARANTIC ENDOCARDITIS**---non-bacterial thrombotic endocarditis secondary to malignancy (usually adenocarcinoma) or SLE (Libman--Sacks endocarditis)

Pathophysiology {#Sec185}
---------------

**SUBTYPES**---important to classify infective endocarditis as acute vs. subacute, native valve vs. prosthetic valve, and right sided vs. left sided**[native heart valve]{.smallcaps}**---usually *S. viridans*, *S. bovis*, enterococci**[prosthetic heart valve]{.smallcaps}**---**\<2 months** (usually coagulase negative staphylococci, may need to treat surgically), **\>1 year** (usually *S. viridans*, *S. bovis*, enterococci)**[injection drug use]{.smallcaps}**---usually *S. aureus* and Gram negative rods. Tricuspid valve most commonly affected**[cancer]{.smallcaps}**---about 50% of patients with *S. bovis* endocarditis also have neoplasms of the GI tract

### Risk Factors for Endocarditis {#Sec186}

**[high risk]{.smallcaps}**---complex cyanotic congenital heart disease (unrepaired or incompletely repaired cyanotic congenital heart disease, including palliative shunts and conduits; completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure; repaired congenital heart disease with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device), surgically constructed systemic pulmonary shunts, previous infective endocarditis, prosthetic heart valve, cardiac transplantation recipients who develop cardiac valvulopathy**[moderate risk]{.smallcaps}**---most other congenital heart diseases, acquired valvular disease (rheumatic heart disease, mitral/aortic/pulmonary/tricuspid stenosis or regurgitation), mitral valve prolapse with valvular regurgitation or leaflet thickening, hypertrophic cardiomyopathy**[low or no risk]{.smallcaps}**---secundum ASD or surgically repaired ASD, VSD, PDA, mitral valve prolapse with thin leaflets in the absence of regurgitation, ischemic heart disease, previous CABG**[non-cardiac]{.smallcaps}**---IDU, poor dental hygiene, long-term hemodialysis, long-term indwelling catheter, procedures (GU, GI, surgical wound infection), diabetes, HIV

Clinical Features {#Sec187}
-----------------

**[history]{.smallcaps}**---fever, murmur, dyspnea, chest pain, anorexia, weight loss, malaise, night sweats, complications (painful nodules, rash, stroke, myocardial infarction, any infections), past medical history (structural heart disease, recent procedures \[dental, GI, GU\], IDU, SLE, malignancy), medications

**[physical]{.smallcaps}**---fever, splinter hemorrhages, clubbing, Osler nodes (tender, subcutaneous nodules in pulp of digits or thenar eminence), Janeway lesions (non-tender, erythematous, hemorrhagic pustular lesions on palms or soles), needle track marks, petechiae over conjunctivae and oral mucosa, Roth spots (pale areas surrounded by hemorrhage on fundoscopic examination), lymphadenopathy, respiratory examination (HF), murmur (regurgitant), splenomegaly, petechiae over legs

**HIGH INDEX OF SUSPICION**---always consider endocarditis in the differential when dealing with fever of unknown origin, persistent bacteremia, HF, MI, myocarditis, pericarditis, stroke, pneumonia, pulmonary embolism, splenic infarction, glomerulonephritis, septic arthritis, and osteomyelitis

Investigations {#Sec188}
--------------

### Basic {#Sec189}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, LDH, ESR, ANA, serology (HBV, HCV, HIV), urinalysis**[microbiology]{.smallcaps}**---blood C&S ×3 (endocarditis protocol and blood C&S ×2 daily until culture negative), sputum Gram stain/AFB/C&S, urine C&S, stool C&S, O&P, C. diff toxin A/B**[imaging]{.smallcaps}**---CXR, echocardiogram (TEE\>TTE), CT chest/abd**ECG**---heart block

Diagnostic and Prognostic Issues {#Sec190}
--------------------------------

### Modified Duke'S Criteria {#Sec191}

**[major]{.smallcaps}**---positive blood culture ×2 (or positive blood culture ×1 for *C. burnetii*), echocardiographic evidence (oscillating intracardiac mass, abscess, new partial dehiscence of a prosthetic valve), new murmur**[minor]{.smallcaps}**---**fever** (\>38°C \[100.4°F\]), **risk factor** (cardiac conditions, IDU), **vascular phenomena** (major arterial emboli, septic pulmonary infarct, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions), **immunologic phenomena** (glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor), **positive blood culture** not meeting major criteria**[diagnosis]{.smallcaps}**---likely endocarditis if 2 major, 1 major plus 2 minor, or 5 minor criteria

**ECHOCARDIOGRAM**---transesophageal echocardiogram (TEE sens 90--100%, spc 95--100%) preferred over transthoracic echocardiogram (TTE sens 50--80%, spc 90%) for detecting vegetations, perivalvular extension of infection and abscesses, diagnosing prosthetic valve endocarditis, and for differentiating between uncomplicated *Staphylococcus aureus* bacteremia and endocarditis

**PROGNOSIS**---mortality of 25--50% for prosthetic valve endocarditis, 35% for Staphylococcal endocarditis and 10% for Streptococcal endocarditis**Related Topics**Aortic Regurgitation (p. 49)Mitral Regurgitation (p. 51)Tricuspid Regurgitation (p. 51)

Management {#Sec192}
----------

**EMPIRIC ANTIBIOTIC THERAPY**---**native valve and non-IDU** (*ampicillin* 2 g IV q4h or *cloxacillin* 2 g IV q4h plus *gentamicin* 1 mg/kg IV q8h, or *vancomycin* 1 g IV q12h plus *gentamicin* 1 mg/kg IV q8h), **native valve and IDU** (*cloxacillin* 2 g IV q4h plus *gentamicin* 1 mg/kg IV q8h or *vancomycin* 1 g IV q12h plus *gentamicin* 1 mg/kg IV q8h), **prosthetic valve** (*vancomycin* 1 g IV q12h plus *gentamicin* 1 mg/kg IV q8h plus *rifampin* 600 mg PO daily)

**TARGETED ANTIBIOTIC THERAPY** (please refer to the Sanford guide to antimicrobial therapy)---**Streptococci** (*penicillin G* 2--3MU IV q4h or *ceftriaxone* 2 g IV/IM q24h ×4 weeks. *Gentamicin* 1 mg/kg IV q24h ×2 weeks may be added in certain circumstances to shorten the course by 2 weeks). **Penicillin-sensitive Enterococci** (*ampicillin* 2 g IV q4h or *vancomycin* 1 g IV q12h ×4--6 weeks, plus *gentamicin* 1 mg/kg IV q8h ×4--6 weeks for native valve). **Penicillin-resistant Enterococci** (*vancomycin* 1 g IV q12h ×6 weeks, plus *gentamicin* 1 mg/kg IV q8h ×6 weeks for native valve). ***S. aureus*** (*cloxacillin* 2 g IV q6h or *nafcillin* or *oxacillin* 3 g IV q6h or *cefazolin* 2 g IV q8h ×2--6 weeks (depending on right- or left- sided valve) ± *gentamicin* 1 mg/kg IV q8h ×3--5days: for native valve). **MRSA** (*vancomycin* 1 g IV q12h ×6 weeks for native valve). **HACEK** (*ceftriaxone* 2 g IV/IM q24h or *ampicillin-sulbactam* 3 g IV q6h or *ciprofloxacin* 500 mg PO BID ×4 weeks). For prosthetic valve infection, therapy is usually longer (by 2--4 weeks) with gentamicin

**SURGERY**---**valvular replacement** (\<10% reinfection rate. See indications below)

Treatment Issues {#Sec193}
----------------

**[indications for surgery]{.smallcaps}**---in the acute period, refractory congestive heart failure is the most important indication. Other indications include perivalvular extension of infection, abscess, microbiologic failure, infection with fungi or untreatable pathogens, Staphylococci on a prosthetic valve, two major emboli events and one major embolus event with residual large mobile vegetation

**[overall recommendations for endocarditis prophylaxis]{.smallcaps}**---only given to patients with the highest risk of developing endocarditis, which include the following:**[high-risk cardiac conditions]{.smallcaps}**---prosthetic cardiac valve, prosthetic material used for cardiac valve repair, unrepaired cyanotic congenital heart disease, completely repaired cyanotic congenital heart disease with residual defects at the site or adjacent to the site of the prosthetic device, cardiac transplant recipients with valvulopathy, previous endocarditis**[procedures]{.smallcaps}** **[oral cavity]{.smallcaps}**---manipulation of gingival or peripical region of teeth, perforation of oral mucosa**[respiratory tract]{.smallcaps}**---tonsillectomy, adenoidectomy, bronchoscopy with a rigid bronchoscope, or flexible bronchoscopy if biopsied**[gi/gu tract]{.smallcaps}**---prophylaxis generally not recommended**[prophylaxis regimens]{.smallcaps}**---give one of the following 30--60 min prior to procedure: *amoxicillin* 2 g PO/IM/IV, *cefazolin* 1 g IV/IM, *ceftriaxone* 1 g IV/IM, *cephalexin* 2 g PO, *clindamycin* 600 mg PO/IM/IV, *azithromycin* 500 mg PO, *clarithromycin* 500 mg PO

Peripheral Vascular Disease {#Sec194}
===========================

**NEJM 2007 356:12**

Differential Diagnosis of Claudication {#Sec195}
--------------------------------------

### Arterial {#Sec196}

**[atherosclerosis]{.smallcaps}[intraluminal occlusion]{.smallcaps}**---embolism, thrombosis, dissection, adventitial cystic disease, arterial fibrodysplasia, arterial tumor, occluded limb aneurysm**[vasculitis]{.smallcaps}**---Takayasu's arteritis, temporal arteritis, thromboangiitis obliterans**[vasospasm]{.smallcaps}DRUGS**---ergot**[fibrosis]{.smallcaps}**---iliac endofibrosis, radiation fibrosis, retroperitoneal fibrosis**[trauma]{.smallcaps}**

**VENOUS**---DVT, thrombophlebitis, venous congestion

**NEUROPATHIC**---spinal stenosis, peripheral neuropathy

**OTHERS**---arthritis (hips, knees), compartment syndrome

Clinical Features {#Sec197}
-----------------

**HISTORY**---pain, discomfort, or fatigue that occurs in leg muscle with exercise and improves with resting (ischemic intermittent claudication is NOT sensitive for peripheral vascular disease), maximum walking distance, trauma, DVT risk factors, past medical history (CAD, HF, AF, stroke, TIA, renal disease, hypertension, cholesterol), medications

### Physical {#Sec198}

**[ankle brachial index]{.smallcaps}** (ABI)---\>1.3 non-compressible calcified vessel, 0.90--1.3 normal, \<0.90 indicates significant narrowing of one or more blood vessels in the legs, \<0.8 intermittent claudication, \<0.4 resting claudication, \<0.25 severe limb-threatening peripheral vascular disease is probably present. An ABI that ↓ by 20% following exercise is diagnostic of peripheral vascular disease, while a normal ABI following exercise eliminates the diagnosis**B** **[uerger's test]{.smallcaps}**---abnormal pallor with elevation of leg 90° for 2 min and deep rubor when lowered for 2 min**[de]{.smallcaps}** **W** **[eese's test]{.smallcaps}**---disappearance of previously palpable distal pulses after walking exercise

**VENOUS INSUFFICIENCY** **EXAMINATION**---hemosiderin deposit, pitting edema, dermatitis, cellulitis, ulcer (with prominent granulation tissue over medial malleolus), superficial venous collaterals (DVT), varicose vein (palpate for tenderness or hardness that may suggest thrombophlebitis), Trendelenburg test (helps to determine whether venous reflux is related to the superficial or deep venous system. Occlude a collapsed superficial vein just below the site of suspected reflux from deep to superficial system. With patient standing, observe refilling of vein. Rapid refilling despite occlusion suggests incompetence of valves in the deep venous system, while slow refilling with occlusion and rapid refilling after occlusion is removed suggests incompetence of valves in the superficial venous system) RATIONAL CLINICAL EXAMINATION SERIES: DOES THE CLINICAL EXAMINATION PREDICT LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE?**LR+LR−History**Claudication3.30.89**Inspection**Wounds (ischemic ulcers and gangrene over lateral malleolus, tips of toes, metatarsal heads, bunion)5.90.98Discolouration2.80.74Atrophy----Absence of hair----**Palpation**Any palpable pulse abnormality (femoral, popliteal, posterior tibial, dorsalis pedis)4.70.38Coolness5.90.92Capillary refill time (firm pressure to planter aspect of great toe for 5 s. Abnormal if \>5 s for normal skin)1.9--**Auscultation**Any bruit (iliac, femoral, popliteal)5.60.39**SPECIAL TESTS**---**ankle brachial index** (ankle SBP by palpation/doppler of posterior tibial or dorsalis pedis pulse divided by brachial SBP), **Buerger test** (raise legs to 90° with patient in supine position. Check for return of rubor as the legs are lowered. Abnormal if angle of circulation \<0° i.e. legs below table), **venous filling time** (raise leg to 45° for 1 min with patient supine position for vein to collapse. With patient then sitting up and legs dangling, determine the time for vein to refill. Abnormal if \>20 s) (LR+ 3.6, LR-- 0.8)**APPROACH**---"for screening patients who require further testing to diagnose peripheral arterial disease, the most useful individual symptoms and signs are: claudication, femoral bruit and a pulse abnormality on palpation. The absence of claudication and the presence of normal pulses decrease the likelihood of moderate to severe disease. When considering patients who are symptomatic with leg complaints, the most useful individual findings are the presence of cool skin, the presence of at least 1 bruit and any palpable pulse abnormality. The absence of any bruit (iliac, femoral and popliteal) and the presence of normal peripheral pulses reduce the likelihood of peripheral arterial disease"**JAMA 2006 295:5** DISTINGUISHING FEATURES OF COMMON CAUSES OF LEG PAIN**ClaudicationSpinal stenosisVenous congestion**PainCramp, tirednessCramp, tiredness, tinglingTightness, burstingSitesButtock, hip, thigh, calf, footButtock, hip, thighGroin, thighWorseWalkingWalking, standingWalkingBetterRestSitting or change in positionLeg elevationOthersVascular dx, ↓ pulseLower back painHistory of DVT

Investigations {#Sec199}
--------------

**BASIC**

**[labs]{.smallcaps}**---CBC, lytes, urea, Cr, fasting glucose, fasting lipids, HbA1C**[ankle brachial index]{.smallcaps}**---with or without exercise**[duplex ultrasound]{.smallcaps}ECG**

**SPECIAL**

**CT/MR angiography[angiography]{.smallcaps}**

Diagnostic Issues {#Sec200}
-----------------

**[diagnostic approach]{.smallcaps}**---ABI \<0.9 is sufficient for the diagnosis of peripheral arterial disease as it suggests \>50% stenosis of peripheral vasculature (sens 90%, spc 98%). Patients with large vessel disease (distal aorta or iliac arteries) may only have abnormal ABI after exercise. Patients with non-compressible vessels should have toe-brachial index done. Perform duplex U/S or CT/MR angiogram if the diagnosis is uncertain or if revascularization is being considered. Digital-subtraction angiograph remains the gold standard

Management {#Sec201}
----------

### Risk Reduction ★Abcdefg★ {#Sec202}

**ASAB** **[lood pressure control]{.smallcaps}** (see HYPERTENSION p. 57)**C** **[holesterol control]{.smallcaps}** (see DYSLIPIDEMIA p. 61)**D** **[iabetic control]{.smallcaps}** (see DIABETES p. 337)**E** **[xercise]{.smallcaps}** (30 min of moderate-intensity exercise 3--4×/week)**F** **[at reduction]{.smallcaps}** (see OBESITY ISSUES p. 403)**G** **[et going to quit smoking!]{.smallcaps}** (see SMOKING ISSUES p. 418)

**[medical]{.smallcaps}**---**antiplatelet** (*ASA* 81--325 mg PO daily, dipyridamole, *clopidogrel* 75 mg PO daily, *cilostazol* 100 mg PO BID), **blood viscosity reducing agent** (*pentoxifylline* 400 mg TID) is of dubious benefit

**[surgical]{.smallcaps}**---**revascularization** (surgery or percutaneous transluminal angioplasty)

Treatment Issues {#Sec203}
----------------

**REVASCULARIZATION**---indicated for patients with significant functional limitations (lifestyle or jobs) despite maximal lifestyle and medical treatment. Not optimal for patients \>40, with non-disabling symptoms, diabetes, significant coronary risk factors, or other diseases associated with high mortality

Specific Entities {#Sec204}
-----------------

**VASCULAR DISEASE FAMILY**---CAD, CVD, PVD, AAA, renal artery stenosis, chronic mesenteric ischemia

**ABDOMINAL AORTIC ANEURYSM**---U.S. Preventative Services Task Force recommends one-time screening with abd U/S for men 65--75 who have ever smoked. Repair is controversial for 4--5 cm \[1.6--2 in.\]; \>5 cm \[\>2 in.\] warrants surgical intervention (risk of spontaneous rupture is 22%/year). Monitor lesions ≤5 cm \[≤2 in.\] with ultrasound regularly (every 6 months if lesions 4 cm \[1.6 in.\], more frequent for bigger lesions). Operative mortality is 4--6% for elective repair, 19% for urgent repair, and 50% for repair of a ruptured aneurysm. No driving if AAA \>5 cm \[\>2 in.\]

### Rational Clinical Examination Series: Does This Patient Have Abdominal Aortic Aneurysm? {#Sec205}

**PALPATION**---to detect abnormal widening of the aortic pulsation (sens 50% for AAA 4--4.9 cm \[1.6--1.9 in.\], sens 76% for AAA ≥5 cm \[≥2 in.\], LR+ 12 and LR-- 0.72 for AAA ≥3 cm \[≥1.2 in.\], LR+ 15.6 and LR-- 0.51 for AAA ≥4 cm \[≥1.6 in.\])

**APPROACH**---"abdominal palpation will detect most AAAs large enough to warrant surgery, but it cannot be relied on to exclude the diagnosis. The sensitivity of palpation appears to be reduced by abdominal obesity. When a ruptured AAA is suspected, imaging studies such as ultrasound or computed tomography should be performed regardless of physical findings"

**JAMA 1999 281:1**

Hypertension {#Sec206}
============

**NEJM 2003 348:7; NEJM 2006 355:4;** **NEJM 2007 357:8**

Differential Diagnosis {#Sec207}
----------------------

### ★0--1-2--3-4★ {#Sec208}

**0** **ESSENTIAL HYPERTENSION**

**1** **ANATOMIC**---aorta (coarctation, aortic dissection)

**2** **RENAL**---renal parenchymal disease (chronic renal failure, polycystic kidney disease), renal artery stenosis

**3** **[  adrenal]{.smallcaps}**---pheochromocytoma, Conn's syndrome, Cushing's syndrome

**4** **SCENTS**

**S** **[uper growth]{.smallcaps}**---acromegaly**C** **[alcium]{.smallcaps}**---hypercalcemia**E** **[strogen or other drugs]{.smallcaps}**---NSAIDs, steroids, oral contraceptives, cocaine, amphetamines, MAO inhibitors, erythropoietin, cyclosporin, tacrolimus, midodrine, alcohol excess**N** **[eurologic]{.smallcaps}**---Cushing's triad (hypertension, bradycardia and respiratory depression associated with increased intracranial pressure)**T** **[hyroid]{.smallcaps}**---hyperthyroidism, hypothyroidism**S** **[leep apnea]{.smallcaps}**

Pathophysiology {#Sec209}
---------------

### Classification of Hypertension {#Sec210}

**[malignant hypertension]{.smallcaps}**---chronic marked hypertension with retinal hemorrhages, exudates, or papilledema**[hypertensive urgency]{.smallcaps}**---\>220/120 mmHg without findings of hypertensive emergency**[hypertensive emergency]{.smallcaps}**---acute severe hypertension with end organ damage such as pulmonary edema, aortic dissection, myocardial infarction, cerebrovascular hemorrhage, papilledema, fundoscopic hemorrhages or exudates, and hypertensive encephalopathy

**ISOLATED SYSTOLIC HYPERTENSION**---younger people tend to have isolated diastolic hypertension (50--60% of patients under 40). With age, large arteries tend to stiffen with decreased elasticity secondary to a combination of atherosclerosis, calcification, and elastin degradation. Thus, isolated systolic hypertension predominates (over 90% of patients over 70)

**HYPERTENSIVE END ORGAN DAMAGE**---ischemic heart disease, peripheral arterial disease, left ventricular hypertrophy, stroke, TIA, microalbuminuria or proteinuria, and chronic kidney disease

### Hypertensive Retinopathy {#Sec211}

**[mild]{.smallcaps}**---**focal arteriolar narrowing** (vasospasm), **generalized arteriolar narrowing** (increased vascular tone due to autoregulation, mild intimal hyperplasia, and hyaline degeneration in sclerotic stage). Subsequently, **arteriovenous nicking** (venous compression by a thickened arteriole, leading to dilation of vein around intersection) and **opacity of arteriolar wall** (widening and accentuation of the central light reflex leading to so-called copper wiring appearance)**[moderate]{.smallcaps}**---**hemorrhages** (blot, dot, or flame shaped due to disruption of the blood--retina barrier), **microaneurysms** (necrosis of the smooth muscles and endothelial cells), **hard** **exudates** (exudation of blood and lipids), and **soft exudates** (cotton wool spots, retinal ischemia)**[malignant]{.smallcaps}**---signs of moderate retinopathy plus swelling of the optic disc**[utility]{.smallcaps}**---the retina provides a window of cerebral circulation. Risk of stroke (and death) increases with degree of retinopathy. Note that the stages may not be sequential

**NEJM 2004 351:22**

Clinical Features {#Sec212}
-----------------

**HISTORY**---blood pressure levels, ambulatory/home monitoring, complications (ischemic heart disease, peripheral arterial disease, left ventricular hypertrophy, stroke, TIA, microalbuminuria or proteinuria, and chronic kidney disease), other cardiac risk factors (smoking, diabetes, dyslipidemia, obesity), past medical history (thyroid, renal, or adrenal disorders), medications (antihypertensives, steroids, illicit drugs)

**PHYSICAL**---vitals (heart rate, blood pressure), obesity (sleep apnea), moon facies and thoracocervical fat pad (Cushing's), upper body better developed and continuous murmur over precordium/back (coarctation), narrowed oropharynx and ↑ neck circumference (OSA), goiter (hyperthyroidism), aortic regurgitation (aortic dissection), striae, renal bruits (renal artery stenosis), abdominal masses (polycystic kidney disease, adrenal tumors), radiofemoral delay, and weak femoral pulses (coarctation). Assess complications including retinopathy, stroke, HF, AAA, and PVD

**MEASURING BLOOD PRESSURE**---**NEJM 2009 360:e6**

Investigations {#Sec213}
--------------

### Basic {#Sec214}

**[labs]{.smallcaps}**---lytes, urea, creatinine, glucose, fasting lipid profile, CRP, urinalysis, urine microalbumin**[24-hour ambulatory blood pressure monitor]{.smallcaps}ECG**

Investigations (cont\'d) {#Sec215}
------------------------

### Secondary Causes Workup {#Sec216}

**[endocrine workup]{.smallcaps}**---Ca, albumin, TSH, serum renin/aldosterone, cortisol, 24-h urine metanephrine and creatinine, serum osmolality, urine osmolality, urine lytes, selective adrenal vein sampling**[renal artery stenosis workup]{.smallcaps}**---renal dopplers, captopril renogram, CT/MR angiogram, renal angiogram**[sleep oximetry test]{.smallcaps}**---if suspect sleep apnea

Diagnostic Issues {#Sec217}
-----------------

### Clinical Diagnosis of Hypertension {#Sec218}

**Hypertensive urgency or emergency during first visit?** Yes=hypertension diagnosedNo=proceed to step 2**What is blood pressure during second visit?** BP ≥180/110 mmHg=hypertension diagnosedBP 140--179/90--109 mmHg=proceed to step 3BP \<140/90 mmHg=continued follow-up**Target organ damage, diabetes, or chronic kidney disease?** Yes=hypertension diagnosedNo=proceed to step 4 for clinic patient, step 6 for ambulatory BP monitoring, or step 7 for home BP monitoring**BP ≥160/100 mmHg during third visit?** Yes=hypertension diagnosedNo=consider ambulatory BP monitoring (step 6) or proceed to step 5**BP ≥140/90 mmHg during fourth or fifth visit?** Yes=hypertension diagnosedNo=continue follow-up**Ambulatory BP monitoring: mean awake BP ≥135/85 mmHg OR mean 24-h BP ≥130/80 mmHg?** Yes=hypertension diagnosedNo=continue followup**Home BP monitoring: average BP ≥135/85 mmHg?** Yes=hypertension diagnosedNo=continue follow-up or proceed to ambulatory BP monitoring (step 6)

**CHEP Guidelines 2009**

<http://www.hypertension.ca>

Acute Management {#Sec219}
----------------

**[acute]{.smallcaps}**---ABC, O~2~, IV

**[hypertensive emergency]{.smallcaps}**---*labetalol* 20 mg IV bolus initially, then 20--80 mg q10min, or 2 mg/min IV infusion (loading) then 2--8 mg/min, maximum total dose of 300 mg. *Nitroprusside* 0.25--0.5 µg/kg/min IV initially, increase by 0.5 µg/kg/min increments, to usually target 3 µg/kg/min (rarely \>4 µg/kg/min, maximum 10 µg/kg/min). *Nicardipine* 5 mg/hr IV initially, titrate to a maximum of 15 mg/hr. *Fenoldopam* 0.1 µg/kg/min IV initially, titrate dose q15min. Consider ICU admission. Workup and treatment of underlying causes once stabilized

**HYPERTENSIVE URGENCY**---*furosemide* 20--40 mg PO/IV ×1 dose. *Nifedipine* 0.25--0.5 mg/kg PO q4--6 h. *Clonidine* 0.1--0.3 mg PO BID. *Captopril* 25--50 mg PO TID. *Labetalol* 5--20 mg IV q15min or *hydralazine* 5--20 mg IV q15min to keep SBP \<170 mmHg. Workup and treatment of underlying cause once stabilized

Long-Term Management {#Sec220}
--------------------

**LIFESTYLE CHANGES**---**healthy diet** (high in fresh fruits, vegetables, and low fat dairy products; low in saturated fat and salt \<100 mmol/day). **Physical** **activity** (optimum 30--60 min of moderate cardiopulmonary activity 4--7×/week). **Reduction in alcohol** (\<2 drinks/day in men and \<1 drink/day in women). **Weight loss** (in those with BMI \>25 kg/m^2^, lose \>5 kg). **Smoke free environment**

### Antihypertensives ★ABCD★ {#Sec221}

**ACE** **[inhibitor]{.smallcaps}**---*ramipril* 2.5--10 mg PO daily-BID, *captopril* 12.5--50 mg PO TID, *perindopril* 2--8 mg PO daily, *lisinopril* 2.5--10 mg PO daily**ARB**---*candesartan* 8--32 mg PO daily, *losartan* 50--100 mg PO daily**[β-blockers]{.smallcaps}**---no longer first line agent for age \>60. *Metoprolol* 50--100 mg BID, *atenolol* 50--100 mg PO daily, *labetalol* 100--400 mg PO TID, *bisoprolol* 5--10 mg PO daily**[calcium channel blockers]{.smallcaps}**---*amlodipine* 2.5--10 mg PO daily, *diltiazem CD* 180--360 mg PO daily**[diuretics]{.smallcaps}**---*hydrochlorothiazide* 12.5--25 mg PO daily, *chlorthalidone* 25 mg PO daily, *spironolactone* 12.5--50 mg PO daily**[α1 agonists]{.smallcaps}**---*clonidine* 0.1--0.5 mg PO BID, *terazosin* 1--20 mg PO daily**[others]{.smallcaps}**---minoxidil, phentolamine, hydralazine

**TREAT UNDERLYING CAUSE**---**renal artery stenosis** (angioplasty with stenting, nephrectomy of atrophic kidney ± endarterectomy)

Treatment Issues {#Sec222}
----------------

### Ace Inhibitors/Angiotensin Receptor Blockers {#Sec223}

**[indications]{.smallcaps}**---HF, post-MI, diabetes, proteinuria, renal failure (with caution), LVH**[contraindications]{.smallcaps}**---pregnancy, ESRD, bilateral RAS**[adverse effects]{.smallcaps}**---cough (less with ARB), angioedema, hyperkalemia

### β-Blockers {#Sec224}

**[indications]{.smallcaps}**---resting tachycardia, HF, migraine, glaucoma, CAD/post-MI**[contraindications]{.smallcaps}**---asthma, severe PVD, Raynaud\'s phenomenon, depression, bradycardia, second or third degree heart block and hypoglycemia-prone diabetics**[adverse effects]{.smallcaps}**---depression, ↓ exercise tolerance, bradycardia, hypotension

### Calcium Channel Blockers {#Sec225}

**[dihydropyridine]{.smallcaps}** (potent vasodilators)---nifedipine, nicardipine, amlodipine, felodipine**[non-dihydropyridine]{.smallcaps}** (heart rate control)---verapamil (cardiac depressant activity), diltiazem (some cardiac depressant, some vasodilator)**[indications]{.smallcaps}**---angina pectoris, recurrent SVT (verapamil), Raynaud\'s phenomenon (dihydropyridine), migraine, heart failure due to diastolic dysfunction, esophageal spasm**[contraindications]{.smallcaps}**---second or third degree heart block (non-dihydropyridine), HF with moderate to marked systolic dysfunction**[adverse effects]{.smallcaps}**---nifedipine (dizziness, headache, flushing, and peripheral edema), verapamil (↓ cardiac contractility, conduction, and constipation), diltiazem (both side effects but a lot less severe)

### Diuretics {#Sec226}

**[indications]{.smallcaps}**---most patients, particularly those of African descent, edema, HF, elderly**[contraindications]{.smallcaps}**---allergy**[adverse effects]{.smallcaps}**---↓ K, hyperuricemia, ↑ cholesterol, ↑ glucose, ↑ insulin resistance, impotence BLOOD PRESSURE TREATMENT TRIGGERS AND TARGETS**Blood pressure (mmHg)When to start therapy?**No macrovascular target organ damageMacrovascular target organ damage or cardiovascular risk factors160/100 140/90**What should the targets be?**Diabetes, chronic kidney diseaseAll others\<130/80\<140/90**CHEP Guidelines 2009**<http://www.hypertension.ca> **OVERALL APPROACH TO CHOICE OF THERAPYConditionDrug of Choice**HTN without other indicationsA/B/C/D → AC/AD/BC/BD → ABC/ACD/BCD/ABD → ABCDAvoid B as first line if age \>60ACEi may be less effective in blacksIsolated systolic hypertensionARB/C1/D → ARB plus either C1 or D → ARB plus C1 plus DAvoid BAnginaACEi/B → ACEi plus B → add C1Prior myocardial infarctionAB → ABCHeart failureAB → ABD (including spironolactone) → ACEi/ARB/B/D. Avoid hydralazine and minoxidil if LVHPrior cerebrovascular diseaseAD → add other agentsPeripheral vascular diseaseA/B/C/D plus ASA.Avoid B if severe PVDDiabetes without nephropathyA/C1/D → AC1/AD → add B or C2Diabetes with nephropathyA → AC/AB/ADCKD ± proteinuriaA → AD → add other agentsAsthmaA/C/D. Avoid BBPHα-blockersPerioperativeB (if moderate to high risk)MigraineBThyrotoxicosisBEssential tremorBPostural hypotensionAvoid vasodilators and diureticsRaynaud'sC (dihydropyridine)GoutDOsteoporosisDHyperkalemiaA/B/C/D. Avoid aldosterone antagonistsHyponatremiaA/B/C. Avoid DPregnancyB/methyldopa/vasodilators. Avoid ACE inhibitors and ARBwhere A=ACE inhibitors/ARBs, B=β-blockers, C=calcium channel blockers, C1=long-acting dihydropyridine CCB, C2=non-dihydropyridine CCB, D=diuretics

Specific Entities {#Sec227}
-----------------

### Renal Artery Stenosis (RAS) {#Sec228}

**[pathophysiology]{.smallcaps}**---causes include atherosclerosis and fibromuscular dysplasia**[clinical features]{.smallcaps}**---systemic atherosclerosis, uncontrolled hypertension, flash pulmonary edema, asymmetrical kidneys, renal failure with ACE inhibitor, and renal bruits**[diagnosis]{.smallcaps}**---MR angiogram (preferred as non-invasive and high sensitivity/specificity), CT angiogram, duplex U/S (anatomic and functional information), captopril-enhanced radioisotope renogram (functional scan but out-of-fashion), contrast angiogram (gold standard)**[treatments]{.smallcaps}**---**medical** (risk factor reduction with emphasis on blood pressure control. ACE inhibitors/ARBs are particularly useful in renal artery stenosis, but should be used with caution in *severe bilateral* renal artery stenosis. Diuretics should be added if hypertension persists), **angioplasty** (consider if severe or refractory hypertension, recurrent flash pulmonary edema, acute significant decline in renal failure due to renal artery stenosis. Unlikely to reverse renal failure if small kidneys or high creatinine \>300 μmol/L \[3.4 mg/dL\]), **surgery**

**NEJM 2001 344:6**

### Differential Diagnosis of Abdominal Bruits {#Sec229}

**[cardiovascular]{.smallcaps}**---abdominal aortic aneurysm, aortocaval fistula**[renal vascular]{.smallcaps}**---renal artery stenosis**GI** **[vascular]{.smallcaps}**---celiac artery compression syndrome, mesenteric ischemia**[hepatic vascular]{.smallcaps}**---cirrhosis, hepatoma, AV malformation, arterioportal fistula, Cruveilhier--Baumgarten sign (cirrhosis, portal hypertension, and caput medusa)**[splenic vascular]{.smallcaps}**---splenic AV fistula, splenic artery dissection, splenic enlargement**[pancreatic vascular]{.smallcaps}**---pancreatic carcinoma

**[rational clinical examination series: is listening for abdominal bruits useful in the evaluation of renovascular hypertension?]{.smallcaps}SensSpcLR+LR−**Systolic and diastolic abdominal bruit39%99%390.6Any epigastric or flank bruit, including isolated systolic bruit63%90%6.40.4Systolic bruit78%64%2.13.5**APPROACH**---"given the high prevalence (7--31%) of innocent abdominal bruits in the younger age groups, it is recommended that if a systolic abdominal bruit is detected in a young, normotensive, asymptomatic individual, no further investigations are warranted. In view of the low sensitivity, the absence of a systolic bruit is not sufficient to exclude the diagnosis of renovascular hypertension. In view of the high specificity, the presence of a systolic bruit (in particular a systolic--diastolic bruit) in a hypertensive patient is suggestive of renovascular hypertension. In view of the lack of evidence to support characterizing bruits as to pitch, intensity and location, bruits should be reported only as systolic or systolic/diastolic"**JAMA 1995 274:16** **Related Topics**Aortic Dissection (p. 25)Hyperaldosteronism (p. 349)Pheochromocytoma (p. 349)

Hyperlipidemia {#Sec230}
==============

**Canadian Cardiovascular Society** **Dyslipidemia Guidelines 2006**

Differential Diagnosis of Hypercholesterolemia {#Sec231}
----------------------------------------------

**PRIMARY**---polygenic, familial (suspect when total cholesterol \>6 mmol/L \[\>232 mg/dL\], LDL \>5 mmol/L \[\>193 mg/dL\])

**SECONDARY**---obesity, diabetes, hypothyroidism, nephrotic syndrome, medications (estrogen, tamoxifen, β-blockers, glucocorticoids)

Differential Diagnosis of Hypertriglyceridemia {#Sec232}
----------------------------------------------

**PRIMARY**---dietary, familial (suspect when TGL \>5 mmol/L \[\>440 mg/dL\])

**SECONDARY**---obesity, diabetes, nephrotic syndrome, hypothyroidism, alcoholism, drugs (tamoxifen, cyclosporine, glucocorticoids)

Differential Diagnosis of Low HDL {#Sec233}
---------------------------------

**PRIMARY**

**SECONDARY**---obesity, smoking, inactivity

Clinical Features {#Sec234}
-----------------

TELLTALE SIGNS**LesionsIIIaIIbIIIIVV**Tendon xanthoma (LDL)✓Palmer xanthoma✓Eruptive xanthoma✓✓✓Xanthelasma✓✓✓✓✓✓Tuberous xanthoma (LDL)✓✓✓

Investigations {#Sec235}
--------------

### Basic {#Sec236}

**[labs]{.smallcaps}**---Cr, fasting glucose, TSH, total chol, TGL, LDL, HDL, apoB, Lp(a), CRP, CK, AST, ALT, ALP, bilirubin, LDH

Management {#Sec237}
----------

**LIFESTYLE CHANGES**---**diet** (↑ fruit and vegetable intake, ↑ mono- and polyunsaturated fats, ↓ saturated fats and trans-fatty acid to \<7% of calories, ↑ omega-3 fatty acid from fish and plant sources, *salmon oil* 3--9 g can ↓TGL). **Exercise**

### risk reduction medications {#Sec238}

**[resins]{.smallcaps}** (↓ LDL, ↑ cholesterol synthesis)---*Cholestyramine* 2--24 g PO daily, *colestipol* 5--30 g PO daily in divided doses. Main side effects include constipation, ↓ vitamin K deficiency, and drug interactions (bind to other drugs and prevent absorption)**HMG** **[-coa reductase inhibitors]{.smallcaps}** (↓ LDL)---*atorvastatin* 10--80 mg daily, *pravastatin* 10--40 mg daily, *rosuvastatin* 2.5--40 mg daily, *simvastatin* 10--80 mg daily. Main side effects include hepatotoxicity, myalgia and myopathy**[fibrates]{.smallcaps}** (↑ HDL, ↓ TGL)---*gemfibrozil* 600--1200 mg daily, *fenofibrate* 67--200 mg daily. Main side effects include GI upset, gallstones, and myalgia**[niacin]{.smallcaps}** (↓ LDL, ↑↑ HDL, ↓ TGL)---*nicotinic acid* 1--3 g. Main side effects include ↑ blood sugar; flushing, hepatotoxicity, and gastric irritation**[aspirin]{.smallcaps}**---*ASA* 81 mg PO daily

**TREAT SECONDARY CAUSES/METABOLIC SYNDROME IF PRESENT**

Treatment Issues {#Sec239}
----------------

TREATMENT TARGETS BASED ON RISK CATEGORY (CCS 2009 Guideline)**High riskModerate riskLow risk**LDL\<2 mmol/L \[\<77 mg/dL\] or ≥50% ↓ LDL\<2 mmol/L\[\<77 mg/dL\] or ≥50% ↓ LDL ≥50% ↓ LDLApoB\<0.80 g/L \[\<80 mg/dL\]\<0.80 g/L\[\<80 mg/dL\]  

### risk categories {#Sec240}

**[high]{.smallcaps}**---≥20% 10-year Framingham risk or established CAD, diabetes, CVD, or PVD. All high risk patients require treatment**[moderate]{.smallcaps}**---10--19% 10-year CAD risk. Consider initiating treatment if LDL \>3.5 mmol/L \[135 mg/dL\], TChol/HDL \>5.0, high sensitivity CRP \>2 mg/L, men age \>50, women age \>60, or significant family history**[low]{.smallcaps}**---\<10% 10-year CAD risk. Consider initiating treatment if LDL ≥5.0 mmol/L \[≥193 mg/dL\]**[utility]{.smallcaps}**---10-year risk calculation is based on Framingham study (gender, age, total chol, HDL, SBP, smoking)

Specific Entities {#Sec241}
-----------------

**METABOLIC SYNDROME** (syndrome X or insulin resistance syndrome)---National Cholesterol Education Program's Adult Treatment Panel (ATC) III report criteria ≥3 of the following five features:**↑ TGL**---≥1.7 mmol/L \[≥150 mg/dL\]**↓ HDL**---♂ \<1.3 mmol/L \[\<50 mg/dL\], ♀ \<1.0 mmol/L \[\<40 mg/dL\]**[insulin resistance]{.smallcaps}**---fasting glucose ≥5.6 mmol/L \[≥110 mg/dL\]**[waist circumference]{.smallcaps}**---♂ \>88 cm \[\>35 in.\], ♀ \>102 cm \[\>40 in.\]**[hypertension]{.smallcaps}**---≥130/85 mmHg or on treatment Other features include hyperuricemia and prothrombotic state FAMILIAL DYSLIPIDEMIA**TypeMechanismLipid profileCardiac riskTreatment(s)Type I**. Hyperchylomicronemialipoprotein lipase deficiency↑ chylo, ↑↑ TAG-Low fat diet**Type IIa**. Hypercholesterolemia↓ LDL receptor. Tendon xanthoma is essential for diagnosis↑ LDL, ↑ CE↑↑Resin, statin, niacin**Type IIb**. Familial combined hyperlipidemia↑ liver VLDL production↑ VLDL, ↑ LDL, ↑ TAG, ↑ CE↑Resin, statin, niacin**Type III**. DysbetalipoproteinemiaapoE Δ. Classically associated with palmer xanthoma↑ chylo-r, ↑ IDL, ↑ TAG, ↑ CE↑Niacin, statin**Type IV**. Hypertriglyceridemia↑ hepatic VLDL production↑ VLDL, ↑ TAG↑Low fat diet, weight loss, fibrate, statin, niacin**Type V**. Mixed hypertriglyceridemia↑ production and ↓ clearance VLDL/chylo↑ VLDL, ↑ chylo, ↑↑ TAG, ↑ CE-Low fat diet, niacin, statin

Smoking Issues {#Sec242}
==============

See SMOKING ISSUES (p. 418)

Approach to ECG {#Sec243}
===============

**AHA/ACCF/HRS 2009 Recommendations** **Circulation 2007 115:10** **Circulation 2009 119:10**

Ten Steps to ECG {#Sec244}
----------------

**ID**---name and age, date, technique (12 lead, calibration, paper speed)**[rate]{.smallcaps}**---normal 60--100 beats/min. 300/150/100/75/60/50 rule**[rhythm]{.smallcaps}**---regular/irregular, wide/narrow complex, sinus, atrial, atrioventricular, ventricular**[axis]{.smallcaps}**---deviation, rotation**PR** **[interval]{.smallcaps}**---normal 120--200 ms; first, second, third degree AV block**QRS** **[interval]{.smallcaps}**---normal 80--110 ms, intraventricular conduction delay 110--120 ms, RBBB, LBBB, LAHB, LPHB**QT** **[interval]{.smallcaps}**---QT \<50% of RR interval; normal QTc 390--460 ms (women), 390--450 ms (men)**[hypertrophy/enlargement]{.smallcaps}**---RAE, LAE, RVH, LVH**[ischemia]{.smallcaps}**---ST elevation/depression, T wave inversion**[infarction]{.smallcaps}**---Q waves**[special conditions]{.smallcaps}**

Chest Leads Placement {#Sec245}
---------------------

**V1**---4^th^ intercostal space, right sternal border

**V2**---4^th^ intercostal space, left sternal border

**V3**---halfway between V2 and V4

**V4**---5^th^ intercostal space, left mid-clavicular line

**V5**---5^th^ intercostal space, left anterior axillary line

**V6**---5^th^ intercostal space, left mid-axillary line

Rate and Rhythm {#Sec246}
---------------

**SINUS**---P before QRS, QRS after P, P upright II+III, P down aVR. Normal (rate 60--100), tachycardia (rate \>100), bradycardia (rate \<60), arrhythmia (variable)

**ATRIAL**---rate 60--80 normally, variable P wave, short PR interval

**JUNCTIONAL** (mid and distal region of AV node)---rate 40--60, no P wave or inverted P wave

**VENTRICULAR** (His bundle, bundle branches, ventricle)---rate 20--40, no P wave

Tachycardia {#Sec247}
-----------

**REGULAR NARROW COMPLEX TACHYCARDIA**---sinus tachycardia, atrial flutter with fixed block (rate 300, 150, 100, 75, 60), supraventricular tachycardia (atrial tachycardia, AV nodal reentry, AV reentrant/WPW orthodromic conduction), accelerated junctional tachycardia

**[irregular narrow complex tachycardia]{.smallcaps}**---sinus tachycardia/arrhythmia, premature atrial contractions, multifocal atrial tachycardia, ectopic atrial tachyarrhythmia with variable block, atrial flutter with variable block, atrial fibrillation

**REGULAR WIDE COMPLEX TACHYCARDIA**---ventricular tachycardia, accelerated idioventricular rhythm, regular narrow complex tachycardia with aberrant conduction, pacemaker-mediated tachyarrhythmia, WPW with antidromic conduction

**IRREGULAR WIDE COMPLEX TACHYCARDIA**---coarse ventricular fibrillation, polymorphic ventricular tachycardia, atrial fibrillation with WPW (anterograde conduction), irregular narrow complex tachycardia with aberrant conduction

**[distinguishing features suggestive of]{.smallcaps}** **VT** **[rather than]{.smallcaps}** **SVT** **[with aberrant conduction]{.smallcaps}**---older age, history of coronary artery disease, AV dissociation (dissociated P waves, fusion beats, capture beats), concordance of precordial leads, QRS width \>160 ms in LBBB or \>140 ms in RBBB, atypical BBB, extreme LAD (--90º to --180º)

Bradycardia and Prolonged PR {#Sec248}
----------------------------

**[sinus]{.smallcaps}**---sinus bradycardia, sick sinus syndrome with sinus pause, bradycardia--tachycardia syndrome (SSS+AF usually)

**AV** **[block]{.smallcaps}**---prolonged PR interval**[first degree]{.smallcaps}**---PR \>200 ms constantly**[second degree]{.smallcaps}** **M** **[obitz type]{.smallcaps}** **I** (Wenckebach)---PR progressively longer and then dropped QRS**M** **[obitz type]{.smallcaps}** **II**---PR constant and then sudden dropped QRS. When any but not all ventricular beats are dropped, second degree block exists**[third degree]{.smallcaps}**---complete blockage with independent atrial and ventricular rhythms

Prolonged QRS---Bundle Branch Block and Hemiblock {#Sec249}
-------------------------------------------------

**[anatomy]{.smallcaps}**---SA node (RCA 59%, LAD 38%, both 3%) → AV node (RCA 90%, LCX 10%) → bundle of His (RCA) → right bundle (LAD), left anterior fascicle (LAD, RCA), and left posterior fascicle (RCA, LAD)

**RBBB**---QRS \>120 ms, slurred S wave in I and V6 and rSR' in V1--3 with R' taller than r. May also see QR' complex in V1 (suggestive of old or new infarct). QRS polarity positive in V1--2. Causes include LAD involvement/anterior infarction, may be benign in young people

**LBBB**---QRS \>120 ms, broad monomorphic R in I and V6, with no Q waves, broad monomorphic S in V1, may have small r wave. QRS polarity negative in V1--2. Causes include hypertension, CAD, dilated cardiomyopathy, rheumatic heart disease, infiltrative diseases, benign or idiopathic

**LEFT** **ANTERIOR HEMIBLOCK**---QRS 100--120 ms, left axis deviation --30° to --90°, qR in I, rS in III, II, and aVF. May be benign, LAD involvement/anterior infarction. Shortcut to diagnosis---I up, II down, aVF down

**LEFT** **POSTERIOR HEMIBLOCK**---right axis deviation 90--180°, normal or slightly widened QRS, rS in I, and qR in III. RCA involvement/anterior infarction

**BIFASCICULAR BLOCK**---RBBB+LAHB, RBBB+LPHB

**TRIFASCICULAR BLOCK**---first degree AV block + bifascicular block

Prolonged QT {#Sec250}
------------

**NORMAL**---QTc=square root (QT in seconds/RR interval in seconds); QT \<50% of RR interval; normal QTc 390--460 ms (women), 390--450 ms (men)

**CAUSES**---**genetic**, **metabolic** (hypokalemia, hypomagnesemia, hypocalcemia), **antiarrhythmics** (quinidine, procainamide, amiodarone, sotalol), **antibiotics** (macrolide, trimethoprim--sulfamethoxazole, fluoroquinolone), **psychotropics** (TCA, SSRI, haloperidol, risperidone), **analgesics** (methadone), **structural heart disease** (HF, LVH, acute ischemia), **others** (HIV, anorexia nervosa, stroke, brain injury)

**PROGRESSION**---may evolve into torsade de pointes, VT, and sudden death (amiodarone less likely)

**TREATMENTS**---remove offending agent(s), overdrive pacing, isoproterenol infusion, magnesium

Hypertrophy Criteria {#Sec251}
--------------------

**RAE**---tall peaked P in II and aVF (\>2.5 mm high); large initial component of biphasic P in V1

**LAE**---wide notched P in II (\>2.5 mm long); biphasic P in V1 with broad negative phase; P wave duration \>120 ms

**LVH**---tall R in aVL (\>11 mm); R in V5 or V6 (whichever is taller) plus S in V1 \>35 mm; R in V5 or R in V6 \>27 mm; poor R wave progression in precordial leads; ST depression and T wave inversion in lateral leads (I, aVL, V5--6) suggestive of ventricular strain; R in aVL plus S in V3 \>28 mm in male or \>20 mm in female (Cornell criteria). Diagnosis difficult with LBBB, consider LVH if S in V1 + R in V5 \>45 mm (Klein criteria)

**RVH**---right axis deviation (\>110°); R\>S wave in V1 and R \>7 mm; persistent S waves V5--6; ST depression and T wave inversion V1--3

**[differential diagnosis for dominant r wave in]{.smallcaps}** **V1**---RV hypertrophy, right bundle branch block, posterior myocardial infarction, pre-excitation (Wolff--Parkinson--White), dextrocardia, Duchenne muscular dystrophy, hypertrophic cardiomyopathy, normal variant, incorrect lead placement, juvenile pattern

Ischemia/Infarct Morphology {#Sec252}
---------------------------

**[hyperacute]{.smallcaps}** **T** **[waves]{.smallcaps}**---starts in seconds

**ST** **[elevation]{.smallcaps}**---transmural injury, starts in minutes

**ST** **[depression]{.smallcaps}**---subendocardial infarction. Consider posterior infarct if in V1/V2

**T** **[wave inversion]{.smallcaps}**---starts in hours, stays for weeks, and flips back in months

**Q** **[waves]{.smallcaps}**---starts in 8 h. If no reperfusion, stays forever. Considered significant if \>1 block wide and height \>1/3 of QRS

**[accelerated idioventricular rhythm]{.smallcaps}**---suggests reperfusion post-infarction (HR \<100, intermittent)

Voltage Criteria {#Sec253}
----------------

**[normal]{.smallcaps}**---QRS \>5 mm high in limb leads, QRS \>10 mm high in precordial leads

**[low]{.smallcaps}**---thick chest wall, COPD, pericarditis, pleural effusion, amyloidosis, myxedema, hemochromatosis

Differential Diagnosis of ST Elevation {#Sec254}
--------------------------------------

**NORMAL MALE PATTERN**---1--3 mm elevation, concave, most marked in V2

**ST** **[elevation of normal variant]{.smallcaps}**---seen in V4--5, short QT, high QRS voltage

**BENIGN EARLY REPOLARIZATION**---most marked in V4 with notching at J point, upright T waves. Reciprocal ST depression in aVR, not in aVL, when limb leads are involved

**ACUTE** **MI**---ST segment with a plateau of shoulder or upsloping, reciprocal behavior between aVL + III

**P** **[rinzmetal's angina]{.smallcaps}**---same as MI but transient

**ACUTE PERICARDITIS**---diffuse ST elevation, ST depression in aVR. Elevation seldom \>5 mm, PR segment depression (best seen in II)

**ACUTE MYOCARDITIS**---diffuse ST elevation, may simulate acute MI/pericarditis

### Aortic Dissection {#Sec255}

**LV** **[aneurysm]{.smallcaps}**---persistent ST elevation after MI

**PULMONARY EMBOLISM**---changes simulating MI seen often in both inferior and anteroseptal leads

**LBBB**---concave, ST segment deviation discordant from QRS. In the presence of LBBB, features suggestive of infarction include concordant ST segment changes (ST elevation ≥1 mm in leads with positive QRS complex and ST depression ≥1 mm in V1--3), disconcordant ST-segment changes (ST elevation ≥5 mm in leads with negative QRS complex)

**LVH**---concave, other features of LVH

**HYPERKALEMIA**---see below

**HYPOTHERMIA**---Osborne waves may be seen

**NEJM 2003 349: 22**

Infarction Zones {#Sec256}
----------------

**TerritoryLeadsArteryComment**InferiorII, III, aVF^a^RCA, LAD^b^RV, SA, AV nodesLateralI, aVL, V5, V6LCX, RCAPosteriorV1i, V2i, V8, V9^c^RCAAnteriorV1--V4^d^LADMassive LVRVR leads (V1), V4RRCAPreload^a^evidence of inferior MI should trigger one to automatically check V4R to assess for RV infarction, which occurs in up to 40% of patients with inferior MI. May see increased JVP and clear lung fields clinically. ST elevation in V4R is diagnostic and prognostic^b^inferior infarcts may be related to either RCA (ST elevation in III\>II and ST depression in I, aVL, or both \>1 mm) or LCX (ST elevation in I, aVL, V5--6 and ST depression in V1--3)^c^i=inverted. ST depression in V1-V2 in a regular ECG should trigger one to automatically request for posterior leads to check for posterior MI. Posterior infarct may be associated with inferior and lateral infarct as these territories are all supplied by RCA^d^V1-V2=septal, V3-V4=anterior

Special Conditions {#Sec257}
------------------

**[hyperthyroidism]{.smallcaps}**---tachycardia, non-specific ST-T changes, biphasic T in V2--V6

**DIGITALIS EFFECT**---slowing SA, AV. Gradual downward sloping/scooping of ST. ST depression in I, II, aVF, V2--V6

**DIGITALIS TOXICITY**---unifocal or multifocal PVCs, first degree heart block, ventricular bigeminy, paroxysmal atrial tachycardia, bidirectional VT

**HYPERKALEMIA**---tall, peaked T wave (especially precordial leads. Definitions of "tall T wave" include a height \>5 mm in limb lead or 10 mm in precordial lead or a T wave height \>50% of the entire QRS excursion in same lead), widen QRS, wide and flat P wave

**HYPOKALEMIA**---flattened T wave/inversion, U wave

**COPD**---RAD, ↓ amplitude, multifocal atrial tachycardia

**HYPERCALCEMIA**---short QT

**HYPOCALCEMIA**---prolonged QT

**W** **[olff--]{.smallcaps}** **P** **[arkinson--]{.smallcaps}** **W** **[hite syndrome]{.smallcaps}**---short PR (\<120 ms), delta wave, prolonged QRS (\>120 ms), symptomatic tachycardia. Pharmacological treatments include amiodarone and procainamide. **AV nodal blocking drugs (adenosine, β-blockers, verapamil/diltiazem, digoxin) are contraindicated in patients with WPW and AF as they may precipitate VF.** Consider catheter ablation if symptomatic arrhythmias, AF, or atrial flutter. If failed, consider surgical ablation

Notes {#Sec258}
=====
